The University of Chicago Header Logo

Richard Schilsky

TitleProfessor Emeritus
InstitutionUniversity of Chicago
DepartmentMedicine
AddressChicago IL 60637
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    U24CA114725     (BERTAGNOLLI, MONICA M.)Jun 6, 2005 - Mar 31, 2016
    NIH
    Cancer and Leukemia Group B Human Specimen Repositories
    Role: Co-Principal Investigator
    U10CA085850     (SCHILSKY, RICHARD L)Sep 30, 2000 - Aug 31, 2007
    NIH
    CALGB STUDIES OF BREAST CANCER IN THE ELDERLY
    Role: Principal Investigator
    R01CA049150     (SCHILSKY, RICHARD L)Dec 1, 1988 - Feb 28, 1993
    NIH
    CELLULAR PHARMACOLOGY OF THE STEREOISOMERS OF LEUCOVORIN
    Role: Principal Investigator
    U10CA044691     (RATAIN, MARK J)Apr 1, 1986 - Mar 31, 2003
    NIH
    CANCER AND LEUKEMIA GROUP B--PET COMMITTEE
    Role: Co-Principal Investigator
    U10CA037447     (BERTAGNOLLI, MONICA M.)Sep 30, 1983 - May 31, 2016
    NIH
    Cancer and Leukemia Group B CCOP Research Base
    Role: Co-Principal Investigator
    U10CA031946     (BERTAGNOLLI, MONICA M.)Apr 1, 1982 - Mar 31, 2015
    NIH
    Cancer and Leukemia Group B
    Role: Co-Principal Investigator
    P30CA014599     (ODUNSI, KUNLE O.)Mar 31, 2024
    NIH
    Cancer Center Support Grant
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Sahai V, Rothe M, Mangat PK, Garrett-Mayer E, Suhag V, Dib EG, Mehmi I, Kadakia KC, Pisick E, Duvivier HL, Le P, Li R, Michelin DP, Wilcox RE, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2024 Apr; 8:e2300527. PMID: 38603652; PMCID: PMC10896467.
      Citations:    
    2. Perez JK, Kleber J, Rothe M, Mangat P, Garrett-Mayer E, Schilsky RL. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study. JCO Precis Oncol. 2024 Mar; 8:e2300615. PMID: 38564684.
      Citations:    Fields:    Translation:Humans
    3. Calfa CJ, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Burness ML, Gogineni K, Rohatgi N, Al Baghdadi T, Conlin A, Gaba A, Hamid O, Krishnamurthy J, Gavini NJ, Gold PJ, Rodon J, Rueter J, Thota R, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Feb; 8:e2300513. PMID: 38354330.
      Citations:    Fields:    Translation:Humans
    4. Krychtiuk KA, Andersson TL, Bodesheim U, Butler J, Curtis LH, Elkind M, Hernandez AF, Hornik C, Lyman GH, Khatri P, Mbagwu M, Murakami M, Nichols G, Roessig L, Young AQ, Schilsky RL, Pagidipati N, Krychtiuk KA, Andersson TL, Butler J, Curtis LH, Elkind M, Hernandez AF, Hornik C, Lyman GH, Khatri P, Mbagwu M, Murakami M, Nichols G, Young AQ, Schilsky RL, Pagidipati N. Drug development for major chronic health conditions-aligning with growing public health needs: Proceedings from a multistakeholder think tank. Am Heart J. 2024 Apr; 270:23-43. PMID: 38242417.
      Citations:    Fields:    Translation:HumansPHPublic Health
    5. Rohatgi N, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Pisick E, Alese OB, Reynolds CM, Thota R, Vaccaro GM, von Mehren M, Arend RC, Chiu VK, Duvivier HL, Gold PJ, Hack K, Marr AS, Winer A, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2023 Sep; 7:e2300279. PMID: 38039429.
      Citations: 1     Fields:    Translation:Humans
    6. Meric-Bernstam F, Rothe M, Mangat PK, Garrett-Mayer E, Gutierrez R, Ahn ER, Cannon TL, Powell S, Krauss JC, Reynolds CM, von Mehren M, Behl D, Calfa CJ, Duvivier HL, Kaplan HG, Livingston MB, Sharma MR, Urba WJ, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Sep; 7:e2300385. PMID: 38096472; PMCID: PMC10735080.
      Citations:    Fields:    Translation:Humans
    7. Duvivier HL, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Al Baghdadi T, Alva AS, Dublis SA, Cannon TL, Calfa CJ, Li R, Behl D, Chiu VK, Gold PJ, Marr AS, Mileham KF, Powell SF, Rodon J, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL, Gregory A, Hinshaw DC. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2023 Nov 20; 41(33):5140-5150. PMID: 37561967.
      Citations: 4     Fields:    Translation:Humans
    8. Mangat PK, Garrett-Mayer E, Perez JK, Schilsky RL. The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial. Clin Trials. 2023 Dec; 20(6):699-707. PMID: 37489819.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    9. Ganti AK, Rothe M, Mangat PK, Garrett-Mayer E, Dib EG, Duvivier HL, Ahn ER, Behl D, Borghaei H, Balmanoukian AS, Gaba A, Li R, Osei-Boateng K, Thota R, Grantham GN, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 06; 7:e2300041. PMID: 37315265.
      Citations: 2     Fields:    Translation:Humans
    10. Jagsi R, Suresh K, Krenz CD, Jones RD, Griffith KA, Perry L, Hawley ST, Zikmund-Fisher B, Spector-Bagdady K, Platt J, De Vries R, Bradbury AR, Bansal P, Kaime M, Patel M, Schilsky RL, Miller RS, Spence R. Health Data Sharing Perspectives of Patients Receiving Care in CancerLinQ-Participating Oncology Practices. JCO Oncol Pract. 2023 08; 19(8):626-636. PMID: 37220315; PMCID: PMC10424907.
      Citations:    Fields:    Translation:Humans
    11. Ahn ER, Rothe M, Mangat PK, Garrett-Mayer E, Ali-Ahmad HM, Chan J, Maitland ML, Patel SR, Reese Z, Balmanoukian AS, Drescher CW, Li R, Tsimberidou AM, Leath CA, O'Lone R, Grantham GN, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 04; 7:e2200609. PMID: 37027810.
      Citations: 4     Fields:    Translation:Humans
    12. Lazar V, Zhang B, Magidi S, Le Tourneau C, Raymond E, Bresson C, Raynaud J, Wunder F, Onn A, Felip E, Tabernero J, Kurzrock R, Rubin E, Schilsky RL, Ducreux M, Batist G. A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology. Ther Adv Med Oncol. 2023; 15:17588359231156382. PMID: 37025260; PMCID: PMC10071163.
      Citations: 2     
    13. Yang ES, Halabi S, Rothe M, Garrett-Mayer E, Mangat PK, Pisick E, Dib E, Burgess EF, Zakem M, Rohatgi N, Bilen MA, O'Lone R, Grantham GN, Schilsky RL. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 02; 7:e2200505. PMID: 36753688.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    14. Schilsky RL, Longo DL. Closing the Gap in Cancer Genomic Testing. N Engl J Med. 2022 Dec 08; 387(23):2107-2110. PMID: 36472952.
      Citations: 6     Fields:    
    15. Klute KA, Rothe M, Garrett-Mayer E, Mangat PK, Nazemzadeh R, Yost KJ, Duvivier HL, Ahn ER, Cannon TL, Alese OB, Krauss JC, Thota R, Calfa CJ, Denlinger CS, O'Lone R, Halabi S, Grantham GN, Schilsky RL. Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2022 Nov; 6:e2200191. PMID: 36409971.
      Citations: 6     Fields:    Translation:Humans
    16. Lazar V, Raynaud J, Magidi S, Bresson C, Galbraith S, Wunder F, Onn A, Girard N, Lassen U, Pramesh CS, Al-Omari A, Ikeda S, Berchem G, Solomon B, Felip E, Tabernero J, Rubin E, Philip T, Porgador A, Berindan-Neagoe I, Schilsky RL, Kurzrock R, Martini JF, Batist G, Blay JY. Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung. Ther Adv Med Oncol. 2022; 14:17588359221133893. PMID: 36324736; PMCID: PMC9618916.
      Citations: 1     
    17. Gupta R, Meric-Bernstam F, Rothe M, Garrett-Mayer E, Mangat PK, D'Andre S, Ahn ER, O'Lone R, Halabi S, Grantham GN, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol. 2022 10; 6:e2200306. PMID: 36315917.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    18. Lazar V, Girard N, Raymond E, Galbraith S, Raynaud J, Bresson C, Solomon B, Magidi S, Nechushtan H, Onn A, Berger R, Chen H, Al-Omari A, Ikeda S, Lassen U, Sekacheva M, Felip E, Tabernero J, Pramesh CS, Girard P, Philip T, Berindan-Neagoe I, Porgador A, Rubin E, Kurzrock R, Schilsky RL, Martini JF, Batist G, Spatz A, Blay JY. Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies. JCO Precis Oncol. 2022 09; 6:e2200072. PMID: 36108261; PMCID: PMC9489166.
      Citations:    Fields:    Translation:HumansCells
    19. Solomon B, Callejo A, Bar J, Berchem G, Bazhenova L, Wunder F, Raynaud J, Girard N, Lee JJ, Sulaiman R, Prouse B, Bresson C, Ventura H, Magidi S, Rubin E, Young B, Onn A, Leyland-Jones B, Schilsky RL, Lazar V, Felip E, Kurzrock R, Saintigny P. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. Cancer Med. 2022 07; 11(14):2790-2800. PMID: 35307972; PMCID: PMC9302335.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    20. Schilsky RL. Beyond the COVID-19 Pandemic: Sustaining and Improving Equitable Cancer Care and Research. Cancer J. 2022 Mar-Apr 01; 28(2):105-106. PMID: 35333493; PMCID: PMC9158731.
      Citations:    Fields:    Translation:HumansPHPublic Health
    21. Nahleh Z, Lyman GH, Schilsky RL, Peterson DE, Tagawa ST, Chavez-MacGregor M, Rumble RB, Gupta S. Use of Biosimilar Medications in Oncology. JCO Oncol Pract. 2022 Mar; 18(3):177-186. PMID: 35041524.
      Citations: 7     Fields:    Translation:Humans
    22. Jones RD, Krenz C, Griffith KA, Spence R, Bradbury AR, De Vries R, Hawley ST, Zon R, Bolte S, Sadeghi N, Schilsky RL, Jagsi R. Patient Experiences, Trust, and Preferences for Health Data Sharing. JCO Oncol Pract. 2022 Mar; 18(3):e339-e350. PMID: 34855514; PMCID: PMC8932496.
      Citations: 1     Fields:    Translation:Humans
    23. Mileham KF, Bruinooge SS, Aggarwal C, Patrick AL, Davis C, Mesenhowski DJ, Spira A, Clayton EJ, Waterhouse D, Moore S, Jazieh AR, Chen RC, Kaltenbaugh M, Williams JH, Gralow JR, Schilsky RL, Garrett-Mayer E. Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. JCO Oncol Pract. 2022 04; 18(4):e426-e441. PMID: 34694907; PMCID: PMC9014452.
      Citations: 10     Fields:    Translation:HumansCells
    24. Ringborg U, Berns A, Celis JE, Heitor M, Baumann M, Henrique R, Aapro M, Basu P, Beets-Tan R, Besse B, van den Eede G, Eggermont A, Galbraith S, Hanahan D, Hofmarcher T, Kallioniemi O, Kondorosi E, Korbel J, Lacombe D, Oberst S, Papatriantafyllou M, Roediger A, Ryll B, Schilsky R, Scocca G, Seruca R, Soares M, Steindorf K, Valentini V, Voest E, Weiderpass E, Wilking N, Zitvogel L, Tabernero J, Schüz J, Cardoso F, Carneiro F, Fröhling S, Garralda E, Jönsson B, Kásler M, Carlos Machado J, Martin-Moreno JM, Meunier F, Nagy P, Nuciforo P, Oliveiera J, Ricciardi W, Wren A. The Porto European Cancer Research Summit 2021. Mol Oncol. 2021 10; 15(10):2507-2543. PMID: 34515408; PMCID: PMC8486569.
      Citations: 2     Fields:    Translation:Humans
    25. Schilsky RL. 'Strategic' development of precision cancer medicine in the United States. Mol Oncol. 2021 07; 15(7):1747-1749. PMID: 34053185; PMCID: PMC8253098.
      Citations: 1     Fields:    Translation:Humans
    26. Cotter G, Alonso Garcia A, George S, Davison B, Figtree G, Prasad K, Rockhold F, Schilsky RL, Stockbridge N, Pitt B, Zannad F, Butler J. What can heart failure trialists learn from oncology trialists? Eur Heart J. 2021 06 21; 42(24):2373-2383. PMID: 34076243.
      Citations: 3     Fields:    Translation:Humans
    27. Lazar V, Magidi S, Girard N, Savignoni A, Massimini G, Bresson C, Berger R, Onn A, Raynaud J, Wunder F, Berindan-Neagoe I, Sekacheva M, Tabernero J, Felip E, Porgador A, Solomon B, Tsimberidou AM, Soria JC, Rubin E, Kurzrock R, Schilsky RL, Martini JF, Braña I, Kleinman C, Batist G. Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. NPJ Precis Oncol. 2021 Apr 28; 5(1):33. PMID: 33911192; PMCID: PMC8080819.
      Citations: 5     
    28. Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, Khalil MF, Ahn ER, Cannon TL, Crilley P, Fisher JG, Haslem DS, Shrestha S, Antonelli KR, Butler NL, Warren SL, Rygiel AL, Ranasinghe S, Bruinooge SS, Schilsky RL. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2021 08 01; 39(22):2443-2451. PMID: 33844595.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    29. Kim ES, Uldrick TS, Schenkel C, Bruinooge SS, Harvey RD, Magnuson A, Spira A, Wade JL, Stewart MD, Vega DM, Beaver JA, Denicoff AM, Ison G, Ivy SP, George S, Perez RP, Spears PA, Tap WD, Schilsky RL. Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement. Clin Cancer Res. 2021 05 01; 27(9):2394-2399. PMID: 33563632.
      Citations: 24     Fields:    Translation:Humans
    30. Harvey RD, Bruinooge SS, Chen L, Garrett-Mayer E, Rhodes W, Stepanski E, Uldrick TS, Ison G, Khozin S, Rubinstein WS, Schenkel C, Miller RS, Komatsoulis GA, Schilsky RL, Kim ES. Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations. Clin Cancer Res. 2021 05 01; 27(9):2430-2434. PMID: 33563634.
      Citations: 16     Fields:    Translation:Humans
    31. Osarogiagbon RU, Vega DM, Fashoyin-Aje L, Wedam S, Ison G, Atienza S, De Porre P, Biswas T, Holloway JN, Hong DS, Wempe MM, Schilsky RL, Kim ES, Wade JL. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group. Clin Cancer Res. 2021 05 01; 27(9):2408-2415. PMID: 33563637; PMCID: PMC8170959.
      Citations: 3     Fields:    Translation:Humans
    32. Smith SM, Wachter K, Burris HA, Schilsky RL, George DJ, Peterson DE, Johnson ML, Markham MJ, Mileham KF, Beg MS, Bendell JC, Dreicer R, Keedy VL, Kimple RJ, Knoll MA, LoConte N, MacKay H, Meisel JL, Moynihan TJ, Mulrooney DA, Mulvey TM, Odenike O, Pennell NA, Reeder-Hayes K, Smith C, Sullivan RJ, Uzzo R. Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. J Clin Oncol. 2021 04 01; 39(10):1165-1184. PMID: 33527845.
      Citations: 38     Fields:    Translation:HumansCellsPHPublic Health
    33. Kurbegov D, Hurley P, Waterhouse DM, Robert NJ, Nowakowski GS, Thompson MA, Bruinooge SS, Schilsky RL, Byatt L, Dempsey K, Dawson C, Hofacker J, Liu J, MacDougall AK, Kim ES. Recommendations to Streamline and Standardize Clinical Trial Site Feasibility Assessments: An ASCO Research Statement. JCO Oncol Pract. 2021 01; 17(1):41-51. PMID: 33405975.
      Citations: 1     Fields:    Translation:Humans
    34. Pennell NA, Dillmon M, Levit LA, Moushey EA, Alva AS, Blau S, Cannon TL, Dickson NR, Diehn M, Gonen M, Gonzalez MM, Hensold JO, Hinyard LJ, King T, Lindsey SC, Magnuson A, Marron J, McAneny BL, McDonnell TM, Mileham KF, Nasso SF, Nowakowski GS, Oettel KR, Patel MI, Patt DA, Perlmutter J, Pickard TA, Rodriguez G, Rosenberg AR, Russo B, Szczepanek C, Smith CB, Srivastava P, Teplinsky E, Thota R, Traina TA, Zon R, Bourbeau B, Bruinooge SS, Foster S, Grubbs S, Hagerty K, Hurley P, Kamin D, Phillips J, Schenkel C, Schilsky RL, Burris HA. American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. J Clin Oncol. 2021 01 10; 39(2):155-169. PMID: 33290128.
      Citations: 36     Fields:    Translation:HumansCells
    35. Al Baghdadi T, Garrett-Mayer E, Halabi S, Mangat PK, Rich P, Ahn ER, Chai S, Rygiel AL, Osayameh O, Antonelli KR, Islam S, Bruinooge SS, Schilsky RL. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 12; 15(6):743-750. PMID: 33068284.
      Citations: 11     Fields:    Translation:Humans
    36. Fisher JG, Tait D, Garrett-Mayer E, Halabi S, Mangat PK, Schink JC, Alvarez RH, Veljovich D, Cannon TL, Crilley PA, Pollock T, Calfa CJ, Al Baghdadi T, Thota R, Fleming N, Cotta JA, Rygiel AL, Warren SL, Schilsky RL. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 12; 15(6):733-741. PMID: 33090333.
      Citations: 11     Fields:    Translation:Humans
    37. Ahn ER, Mangat PK, Garrett-Mayer E, Halabi S, Dib EG, Haggstrom DE, Alguire KB, Calfa CJ, Cannon TL, Crilley PA, Gaba AG, Marr AS, Sangal A, Thota R, Antonelli KR, Islam S, Rygiel AL, Bruinooge SS, Schilsky RL. Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2020 Nov; 4:757-766. PMID: 35050752.
      Citations: 32     Fields:    
    38. Jones RD, Krenz C, Griffith KA, Spence R, Bradbury AR, De Vries R, Hawley ST, Zon R, Bolte S, Sadeghi N, Schilsky RL, Jagsi R. Governance of a Learning Health Care System for Oncology: Patient Recommendations. JCO Oncol Pract. 2021 04; 17(4):e479-e489. PMID: 33095694; PMCID: PMC8257992.
      Citations: 5     Fields:    Translation:Humans
    39. Cree IA, Indave Ruiz BI, Zavadil J, McKay J, Olivier M, Kozlakidis Z, Lazar AJ, Hyde C, Holdenrieder S, Hastings R, Rajpoot N, Rous B, Zenklusen JC, Normanno N, Schilsky RL, IC3R participants, de la Fouchardiere A. The International Collaboration for Cancer Classification and Research. Int J Cancer. 2021 02 01; 148(3):560-571. PMID: 32818326; PMCID: PMC7756795.
      Citations: 13     Fields:    Translation:Humans
    40. Wang F, Schilsky RL, Page D, Califf RM, Cheung K, Wang X, Pang H. Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials. JAMA Netw Open. 2020 10 01; 3(10):e2014661. PMID: 33030549; PMCID: PMC7545295.
      Citations: 1     Fields:    Translation:Humans
    41. Schilsky RL. The National Clinical Trials Network and the cooperative groups: The road not taken. Cancer. 2020 12 01; 126(23):5008-5013. PMID: 32970349.
      Citations: 1     Fields:    Translation:Humans
    42. Schilsky RL, Nass S, Le Beau MM, Benz EJ. Progress in Cancer Research, Prevention, and Care. N Engl J Med. 2020 Sep 03; 383(10):897-900. PMID: 32877579.
      Citations: 13     Fields:    Translation:Humans
    43. Jazieh AR, Chan SL, Curigliano G, Dickson N, Eaton V, Garcia-Foncillas J, Gilmore T, Horn L, Kerr DJ, Lee J, Mathias C, Pierce L, Rogado A, Schilsky RL, Soria JC, Warner JL, Yoshida K, Nogueira-Rodrigues A. Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. JCO Glob Oncol. 2020 Sep; 6:1461-1471. PMID: 32997537; PMCID: PMC7529523.
      Citations: 32     Fields:    Translation:HumansCellsPHPublic Health
    44. Levit LA, Byatt L, Lyss AP, Paskett ED, Levit K, Kirkwood K, Schenkel C, Schilsky RL. Closing the Rural Cancer Care Gap: Three Institutional Approaches. JCO Oncol Pract. 2020 07; 16(7):422-430. PMID: 32574128.
      Citations: 93     Fields:    Translation:Humans
    45. Waterhouse DM, Harvey RD, Hurley P, Levit LA, Kim ES, Klepin HD, Mileham KF, Nowakowski G, Schenkel C, Davis C, Bruinooge SS, Schilsky RL. Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey. JCO Oncol Pract. 2020 Jul; 16(7):417-421. PMID: 32396491.
      Citations: 110     Fields:    Translation:HumansCellsPHPublic Health
    46. Schilsky RL. Talking the Talk About Tumor Genomic Testing. J Natl Cancer Inst. 2020 05 01; 112(5):436-437. PMID: 31675090; PMCID: PMC7225677.
      Citations:    Fields:    Translation:Humans
    47. Jones RD, Krenz C, Gornick M, Griffith KA, Spence R, Bradbury AR, De Vries R, Hawley ST, Hayward RA, Zon R, Bolte S, Sadeghi N, Schilsky RL, Jagsi R. Patient Preferences Regarding Informed Consent Models for Participation in a Learning Health Care System for Oncology. JCO Oncol Pract. 2020 09; 16(9):e977-e990. PMID: 32352881; PMCID: PMC7846056.
      Citations: 7     Fields:    Translation:Humans
    48. Hudis CA, Schilsky RL. Reply to M. Hutton-Potts and A.M. Joshua. JCO Oncol Pract. 2020 05; 16(5):285-286. PMID: 32240070.
      Citations:    Fields:    
    49. Bertagnolli MM, Anderson B, Norsworthy K, Piantadosi S, Quina A, Schilsky RL, Miller RS, Khozin S. Status Update on Data Required to Build a Learning Health System. J Clin Oncol. 2020 05 10; 38(14):1602-1607. PMID: 32209005; PMCID: PMC7213586.
      Citations: 12     Fields:    Translation:Humans
    50. Markham MJ, Wachter K, Agarwal N, Bertagnolli MM, Chang SM, Dale W, Diefenbach CSM, Rodriguez-Galindo C, George DJ, Gilligan TD, Harvey RD, Johnson ML, Kimple RJ, Knoll MA, LoConte N, Maki RG, Meisel JL, Meyerhardt JA, Pennell NA, Rocque GB, Sabel MS, Schilsky RL, Schneider BJ, Tap WD, Uzzo RG, Westin SN. Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2020 04 01; 38(10):1081. PMID: 32013670.
      Citations: 58     Fields:    Translation:Humans
    51. Garrett-Mayer E, Kaltenbaugh MW, Spence R, Bruinooge SS, Hudis CA, Michels D, Schilsky RL. Discrepancies in Financial Self-Disclosures and Open Payments Reporting Among Authors of Clinical Oncology Research Studies. J Clin Oncol. 2020 02 10; 38(5):480-487. PMID: 31815584.
      Citations: 1     Fields:    Translation:Humans
    52. Balogh EP, Bindman AB, Eckhardt SG, Halabi S, Harvey RD, Jaiyesimi I, Miksad R, Moses HL, Nass SJ, Schilsky RL, Sun S, Torrente JM, Warren KE. Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. Oncologist. 2020 03; 25(3):e405-e411. PMID: 32162805; PMCID: PMC7066705.
      Citations:    Fields:    Translation:Humans
    53. Balogh EP, Bindman AB, Eckhardt SG, Halabi S, Harvey RD, Jaiyesimi I, Miksad R, Moses HL, Nass SJ, Schilsky RL, Sun S, Torrente JM, Warren KE. Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. Oncologist. 2019 Dec 04. PMID: 31801899.
      Citations:    
    54. Al Baghdadi T, Halabi S, Garrett-Mayer E, Mangat PK, Ahn ER, Sahai V, Alvarez RH, Kim ES, Yost KJ, Rygiel AL, Antonelli KR, Butler NL, Bruinooge SS, Schilsky RL. Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2019 Dec; 3:1-8. PMID: 35100714.
      Citations: 25     Fields:    
    55. Dinan MA, Lyman GH, Schilsky RL, Hayes DF. Proposal for Value-Based, Tiered Reimbursement for Tumor Biomarker Tests to Promote Innovation and Evidence Generation. JCO Precis Oncol. 2019 Dec; 3:1-10. PMID: 35100733.
      Citations: 8     Fields:    
    56. Jagsi R, Griffith KA, Jones RD, Krenz C, Gornick M, Spence R, De Vries R, Hawley ST, Zon R, Bolte S, Sadeghi N, Schilsky RL, Bradbury AR. Effect of Public Deliberation on Patient Attitudes Regarding Consent and Data Use in a Learning Health Care System for Oncology. J Clin Oncol. 2019 12 01; 37(34):3203-3211. PMID: 31577472; PMCID: PMC6881101.
      Citations: 14     Fields:    Translation:Humans
    57. van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P, Schilsky RL, de Leng WWJ, Huitema ADR, Nuijen B, Nederlof PM, van Herpen CML, de Groot DJA, Devriese LA, Hoeben A, de Jonge MJA, Chalabi M, Smit EF, de Langen AJ, Mehra N, Labots M, Kapiteijn E, Sleijfer S, Cuppen E, Verheul HMW, Gelderblom H, Voest EE. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019 10; 574(7776):127-131. PMID: 31570881.
      Citations: 73     Fields:    Translation:Humans
    58. Bruinooge SS, Sherwood S, Grubbs S, Schilsky RL. Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies. J Oncol Pract. 2019 11; 15(11):575-583. PMID: 31386607.
      Citations: 4     Fields:    Translation:Humans
    59. Nass SJ, Cohen MB, Nayar R, Zutter MM, Balogh EP, Schilsky RL, Hricak H, Elenitoba-Johnson KSJ. Improving Cancer Diagnosis and Care: Patient Access to High-Quality Oncologic Pathology. Oncologist. 2019 10; 24(10):1287-1290. PMID: 31366725; PMCID: PMC6795152.
      Citations: 6     Fields:    Translation:Humans
    60. Burd A, Schilsky RL, Byrd JC, Levine RL, Papadimitrakopoulou VA, Herbst RS, Redman MW, Druker BJ, Gandara DR. Challenges and approaches to implementing master/basket trials in oncology. Blood Adv. 2019 07 23; 3(14):2237-2243. PMID: 31337605; PMCID: PMC6650731.
      Citations: 4     Fields:    Translation:Humans
    61. Kaufman HL, Atkins MB, Subedi P, Wu J, Chambers J, Joseph Mattingly T, Campbell JD, Allen J, Ferris AE, Schilsky RL, Danielson D, Lichtenfeld JL, House L, Selig WKD. The promise of Immuno-oncology: implications for defining the value of cancer treatment. J Immunother Cancer. 2019 05 17; 7(1):129. PMID: 31101066; PMCID: PMC6525438.
      Citations: 42     Fields:    Translation:Humans
    62. Nass SJ, Cogle CR, Brink JA, Langlotz CP, Balogh EP, Muellner A, Siegal D, Schilsky RL, Hricak H. Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging Expertise. J Clin Oncol. 2019 07 10; 37(20):1690-1694. PMID: 31050908; PMCID: PMC6638597.
      Citations: 5     Fields:    Translation:Humans
    63. Rodon J, Soria JC, Berger R, Rubin E, Kugel A, Tsimberidou A, Ackerstein A, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, Raynaud J, Mendelsohn J, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R, Miller WH, Saintigny P, Braña I, Martini JF, Batist G. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019 05; 25(5):751-758. PMID: 31011205; PMCID: PMC6599610.
      Citations: 208     Fields:    Translation:HumansCTClinical Trials
    64. Cherny NI, de Vries EGE, Schilsky RL. Letter to the Editor: When Expertly Applied, ESMO-MCBS and ASCO Net Health Benefit Scores Usually Agree. J Natl Compr Canc Netw. 2019 04 01; 17(4):xxi. PMID: 30959465.
      Citations:    Fields:    Translation:Humans
    65. Polite BN, Seid JE, Freeman M, Levit LA, Kirkwood MK, Schenkel C, Bruinooge SS, Schilsky RL. State of Cancer Care in America: Reflections on an Inaugural Year. J Oncol Pract. 2019 04; 15(4):163-165. PMID: 30856037.
      Citations:    Fields:    Translation:Humans
    66. Levit LA, Kim ES, McAneny BL, Nadauld LD, Levit K, Schenkel C, Schilsky RL. Implementing Precision Medicine in Community-Based Oncology Programs: Three Models. J Oncol Pract. 2019 06; 15(6):325-329. PMID: 30802151.
      Citations: 35     Fields:    Translation:Humans
    67. Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez-MacGregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE. Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2019 04 01; 37(10):834-849. PMID: 30702028.
      Citations: 31     Fields:    Translation:Humans
    68. Cherny NI, de Vries EGE, Dafni U, Garrett-Mayer E, McKernin SE, Latino NJ, Douillard JY, Schnipper LE, Somerfield MR, Bogaerts J, Karlis D, Zygoura P, Vervita K, Pentheroudakis G, Tabernero J, Zielinski C, Wollins DS, Schilsky RL, Piccart M. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. J Clin Oncol. 2019 02 01; 37(4):336-349. PMID: 30707056.
      Citations: 46     Fields:    Translation:Humans
    69. Nass SJ, Rothenberg ML, Pentz R, Hricak H, Abernethy A, Anderson K, Gee AW, Harvey RD, Piantadosi S, Bertagnolli MM, Schrag D, Schilsky RL. Accelerating anticancer drug development - opportunities and trade-offs. Nat Rev Clin Oncol. 2018 12; 15(12):777-786. PMID: 30275514.
      Citations: 17     Fields:    Translation:Humans
    70. Freedman AN, Klabunde CN, Wiant K, Enewold L, Gray SW, Filipski KK, Keating NL, Leonard DGB, Lively T, McNeel TS, Minasian L, Potosky AL, Rivera DR, Schilsky RL, Schrag D, Simonds NI, Sineshaw HM, Struewing JP, Willis G, de Moor JS. Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States. JCO Precis Oncol. 2018 Nov; 2:1-13. PMID: 35135159.
      Citations: 62     Fields:    
    71. Tsimberidou AM, Levit LA, Schilsky RL, Averbuch SD, Chen D, Kirkwood JM, McShane LM, Sharon E, Mileham KF, Postow MA. Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. J Clin Oncol. 2019 01 01; 37(1):72-80. PMID: 30339040; PMCID: PMC6354771.
      Citations: 8     Fields:    Translation:Humans
    72. Tsimberidou AM, Levit LA, Schilsky RL, Averbuch SD, Chen D, Kirkwood JM, McShane LM, Sharon E, Mileham KF, Postow MA. Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement. J Immunother Cancer. 2018 10 19; 6(1):108. PMID: 30340549; PMCID: PMC6195705.
      Citations: 10     Fields:    Translation:Humans
    73. Silverman LR, Norton L, Schilsky RL. In Memoriam: James Frederick Holland, 1925 to 2018. J Clin Oncol. 2018 Sep 10; 36(26):2665-2668. PMID: 30052481.
      Citations:    
    74. Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KA, Stella PJ, Voest E, Yost KJ, Perlmutter J, Pinto N, Kim ES, Schilsky RL. Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2018; 2018. PMID: 30603737; PMCID: PMC6312096.
      Citations: 68     Fields:    
    75. Goey KKH, Glimelius B, Adams RA, Arnold D, Berlin JD, de Gramont A, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M, Sørbye H, André T, Bodoky G, Díaz-Rubio E. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. Eur J Cancer. 2018 09; 100:35-45. PMID: 29936065.
      Citations: 15     Fields:    Translation:HumansCells
    76. Kirkwood MK, Hanley A, Bruinooge SS, Garrett-Mayer E, Levit LA, Schenkel C, Seid JE, Polite BN, Schilsky RL. The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey. J Oncol Pract. 2018 07; 14(7):e412-e420. PMID: 29906211.
      Citations: 50     Fields:    Translation:Humans
    77. Polite BN, Seid JE, Levit LA, Kirkwood MK, Schenkel C, Bruinooge SS, Grubbs SS, Kamin DY, Schilsky RL. A New Look at the State of Cancer Care in America. J Oncol Pract. 2018 07; 14(7):397-399. PMID: 29906212.
      Citations:    Fields:    Translation:Humans
    78. Schilsky RL. Access versus evidence: The regulators' dilemma. Clin Trials. 2018 06; 15(3):240-242. PMID: 29871504.
      Citations: 1     Fields:    
    79. Lyman GH, Zon R, Harvey RD, Schilsky RL. Reply to S.D. Lucio. J Clin Oncol. 2018 07 10; 36(20):2127. PMID: 29847292.
      Citations:    Fields:    Translation:Humans
    80. Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, Opportunities, and Reality of Biosimilar Medications. N Engl J Med. 2018 May 24; 378(21):2036-2044. PMID: 29791832.
      Citations: 26     Fields:    Translation:Humans
    81. Schilsky RL, Schnipper LE. Hans Christian Andersen and the Value of New Cancer Treatments. J Natl Cancer Inst. 2018 05 01; 110(5):441-442. PMID: 29244175.
      Citations: 4     Fields:    Translation:Humans
    82. Schilsky RL. A New IDEA in Adjuvant Chemotherapy for Colon Cancer. N Engl J Med. 2018 03 29; 378(13):1242-1244. PMID: 29590539.
      Citations: 3     Fields:    Translation:Humans
    83. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Arch Pathol Lab Med. 2018 10; 142(10):1242-1253. PMID: 29504834.
      Citations: 59     Fields:    Translation:Humans
    84. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018 06 01; 36(16):1631-1641. PMID: 29504847.
      Citations: 360     Fields:    Translation:Humans
    85. Schnipper LE, Schilsky RL. Are Value Frameworks Missing the Mark When Considering Long-term Benefits From Immuno-oncology Drugs? JAMA Oncol. 2018 03 01; 4(3):333-334. PMID: 29285543.
      Citations: 5     Fields:    Translation:Humans
    86. Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, Zon R, Francisco M, Green S, Sherwood S, Harvey RD, Schilsky RL. American Society of Clinical Oncology Statement: Biosimilars in Oncology. J Clin Oncol. 2018 04 20; 36(12):1260-1265. PMID: 29443651.
      Citations: 32     Fields:    Translation:Humans
    87. Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran RB, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-Galindo C, Schilsky RL, Sznol M, Westin SN, Burstein H. Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2018 04 01; 36(10):1020-1044. PMID: 29380678.
      Citations: 49     Fields:    Translation:Humans
    88. Moscow JA, Fojo T, Schilsky RL. The evidence framework for precision cancer medicine. Nat Rev Clin Oncol. 2018 03; 15(3):183-192. PMID: 29255239.
      Citations: 58     Fields:    Translation:Humans
    89. Levit LA, Perez RP, Smith DC, Schilsky RL, Hayes DF, Vose JM. Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. J Clin Oncol. 2018 02 20; 36(6):617-623. PMID: 29236570.
      Citations: 11     Fields:    Translation:Humans
    90. Conley RB, Dickson D, Zenklusen JC, Al Naber J, Messner DA, Atasoy A, Chaihorsky L, Collyar D, Compton C, Ferguson M, Khozin S, Klein RD, Kotte S, Kurzrock R, Lin CJ, Liu F, Marino I, McDonough R, McNeal A, Miller V, Schilsky RL, Wang LI. Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus. Cell. 2017 Nov 16; 171(5):982-986. PMID: 29149611.
      Citations: 5     Fields:    Translation:Humans
    91. Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, Uldrick TS, Lichtman SM, Roach N, Beaver JA, Sridhara R, Hesketh PJ, Denicoff AM, Garrett-Mayer E, Rubin E, Multani P, Prowell TM, Schenkel C, Kozak M, Allen J, Sigal E, Schilsky RL. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. J Clin Oncol. 2017 Nov 20; 35(33):3737-3744. PMID: 28968170; PMCID: PMC5692724.
      Citations: 164     Fields:    Translation:Humans
    92. Schilsky RL. Guideposts on the journey to value. Ann Oncol. 2017 10 01; 28(10):2325-2326. PMID: 28961824.
      Citations:    Fields:    
    93. Schlemmer HP, Bittencourt LK, D'Anastasi M, Domingues R, Khong PL, Lockhat Z, Muellner A, Reiser MF, Schilsky RL, Hricak H. Global Challenges for Cancer Imaging. J Glob Oncol. 2018 09; 4:1-10. PMID: 30241164; PMCID: PMC6180759.
      Citations: 17     Fields:    Translation:Humans
    94. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB, Mulkerin DL, Mayer RJ, Blanke C. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 06 20; 317(23):2392-2401. PMID: 28632865; PMCID: PMC5545896.
      Citations: 382     Fields:    Translation:Humans
    95. Schnipper LE, Schilsky RL. Converging on the Value of Value Frameworks. J Clin Oncol. 2017 08 20; 35(24):2732-2734. PMID: 28586244.
      Citations: 3     Fields:    Translation:Humans
    96. Schnipper LE, Schilsky RL. Reply to J.P. Jansen, A. Messori et al, and H.S.L. Jim et al. J Clin Oncol. 2017 04 01; 35(10):1134. PMID: 28165893.
      Citations:    Fields:    Translation:Humans
    97. Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017 04 20; 35(12):1341-1367. PMID: 28148207.
      Citations: 40     Fields:    Translation:Humans
    98. Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F. Reply to L. Casadaban et al. J Clin Oncol. 2017 04 20; 35(12):1373-1374. PMID: 28113023.
      Citations:    Fields:    Translation:HumansCells
    99. Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, Mendelsohn J, Kurzrock R. Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. JAMA Oncol. 2016 Nov 01; 2(11):1452-1459. PMID: 27273579.
      Citations: 155     Fields:    Translation:Humans
    100. Schilsky RL. Finding the Evidence in Real-World Evidence: Moving from Data to Information to Knowledge. J Am Coll Surg. 2017 01; 224(1):1-7. PMID: 27989954.
      Citations: 15     Fields:    Translation:Humans
    101. Pang HH, Wang X, Stinchcombe TE, Wong ML, Cheng P, Ganti AK, Sargent DJ, Zhang Y, Hu C, Mandrekar SJ, Redman MW, Manola JB, Schilsky RL, Cohen HJ, Bradley JD, Adjei AA, Gandara D, Ramalingam SS, Vokes EE. Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. J Clin Oncol. 2016 11 20; 34(33):3992-3999. PMID: 27646951; PMCID: PMC5477832.
      Citations: 44     Fields:    Translation:Humans
    102. Agiro A, Ma Q, Acheson AK, Wu SJ, Patt DA, Barron JJ, Malin JL, Rosenberg A, Schilsky RL, Lyman GH. Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer. J Clin Oncol. 2016 11 10; 34(32):3872-3879. PMID: 27646945.
      Citations: 7     Fields:    Translation:Humans
    103. Schilsky R, Davies W. Highlights from the 2016 WIN Symposium, 27-29 June 2016, Paris: personalised therapy beyond next-generation sequencing. Ecancermedicalscience. 2016; 10:669. PMID: 27610195; PMCID: PMC5014556.
      Citations:    
    104. Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F. Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). J Clin Oncol. 2016 09 01; 34(25):3047-53. PMID: 27432924; PMCID: PMC5012711.
      Citations: 16     Fields:    Translation:Humans
    105. Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Vose JM, Schilsky RL. Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. J Clin Oncol. 2016 08 20; 34(24):2925-34. PMID: 27247218.
      Citations: 212     Fields:    Translation:Humans
    106. Disch J, Feeley TW, Mason DJ, Schilsky RL, Stovall EL, Nasso SF. Transformation of Health Care - Perspectives of Opinion Leaders. Semin Oncol Nurs. 2016 05; 32(2):172-82. PMID: 27137474.
      Citations: 2     Fields:    Translation:Humans
    107. Jardim DL, Schwaederle M, Lee JJ, Wei C, Mendelsohn J, Schilsky RL, Kurzrock R. Response. J Natl Cancer Inst. 2016 Mar; 108(3):djw001. PMID: 26912651.
      Citations:    Fields:    Translation:Humans
    108. Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2016 Mar 20; 34(9):987-1011. PMID: 26846975; PMCID: PMC5075244.
      Citations: 58     Fields:    Translation:Humans
    109. Allegra CJ, Rumble RB, Schilsky RL. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 Summary. J Oncol Pract. 2016 Feb; 12(2):180-1. PMID: 26443838.
      Citations: 13     Fields:    Translation:Humans
    110. Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, Schilsky RL. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol. 2016 Jan 10; 34(2):179-85. PMID: 26438111.
      Citations: 122     Fields:    Translation:Humans
    111. Schilsky RL, Wehrwein P. Gains Against Cancer, But Enter 'Financial Toxicity'. Manag Care. 2015 Oct; 24(10):46-7, 52-4. PMID: 26665715.
      Citations: 3     Fields:    
    112. Jardim DL, Fontes Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst. 2015 Nov; 107(11). PMID: 26378224; PMCID: PMC4857149.
      Citations: 91     Fields:    Translation:Humans
    113. Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015 Nov 10; 33(32):3817-25. PMID: 26304871; PMCID: PMC4737863.
      Citations: 209     Fields:    Translation:Humans
    114. Schilsky RL. Highlights from the 2015 WIN Symposium: novel targets, innovative agents, and advanced technologies-a WINning strategy? Ecancermedicalscience. 2015; 9:564. PMID: 26316885; PMCID: PMC4544575.
      Citations:    
    115. Kim ES, Bernstein D, Hilsenbeck SG, Chung CH, Dicker AP, Ersek JL, Stein S, Khuri FR, Burgess E, Hunt K, Ivy P, Bruinooge SS, Meropol N, Schilsky RL. Modernizing Eligibility Criteria for Molecularly Driven Trials. J Clin Oncol. 2015 Sep 01; 33(25):2815-20. PMID: 26195710.
      Citations: 36     Fields:    Translation:Humans
    116. Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Schilsky RL. American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. J Clin Oncol. 2015 Aug 10; 33(23):2563-77. PMID: 26101248; PMCID: PMC5015427.
      Citations: 296     Fields:    Translation:Humans
    117. Lazar V, Rubin E, Depil S, Pawitan Y, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R, Martini JF. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget. 2015 Jun 10; 6(16):14139-52. PMID: 25944621; PMCID: PMC4546456.
      Citations: 11     Fields:    Translation:HumansCells
    118. Tejpar S, Shen L, Wang X, Schilsky RL. Integrating biomarkers in colorectal cancer trials in the West and China. Nat Rev Clin Oncol. 2015 Sep; 12(9):553-60. PMID: 25963094.
      Citations: 5     Fields:    Translation:Humans
    119. Ratain MJ, Geary D, Undevia SD, Coronado C, Alfaro V, Iglesias JL, Schilsky RL, Miguel-Lillo B. First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. Invest New Drugs. 2015 Aug; 33(4):901-10. PMID: 25947566.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    120. Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol. 2015 Aug; 26(8):1791-8. PMID: 25908602; PMCID: PMC5006164.
      Citations: 35     Fields:    Translation:Humans
    121. McClellan MB, Daniel GW, Dickson D, Perlmutter J, Berger DP, Miller V, Nussbaum S, Malin J, Romine MH, Schilsky RL. Improving evidence developed from population-level experience with targeted agents. Clin Pharmacol Ther. 2015 May; 97(5):478-87. PMID: 25676878.
      Citations: 2     Fields:    Translation:HumansCells
    122. Mendelsohn J, Ringborg U, Schilsky R. Innovative clinical trials for development of personalized cancer medicine. Mol Oncol. 2015 May; 9(5):933-4. PMID: 25772590; PMCID: PMC5528749.
      Citations: 3     Fields:    Translation:Humans
    123. Marrone M, Schilsky RL, Liu G, Khoury MJ, Freedman AN. Opportunities for translational epidemiology: the important role of observational studies to advance precision oncology. Cancer Epidemiol Biomarkers Prev. 2015 Mar; 24(3):484-9. PMID: 25750251; PMCID: PMC4679177.
      Citations: 6     Fields:    Translation:Humans
    124. Fleming GF, Schumm P, Friberg G, Ratain MJ, Njiaju UO, Schilsky RL. Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion. BMC Cancer. 2015 Feb 18; 15:69. PMID: 25885822; PMCID: PMC4336691.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    125. Schully SD, Carrick DM, Mechanic LE, Srivastava S, Anderson GL, Baron JA, Berg CD, Cullen J, Diamandis EP, Doria-Rose VP, Goddard KA, Hankinson SE, Kushi LH, Larson EB, McShane LM, Schilsky RL, Shak S, Skates SJ, Urban N, Kramer BS, Khoury MJ, Ransohoff DF. Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. J Natl Cancer Inst. 2015 Apr; 107(4). PMID: 25688116; PMCID: PMC4342676.
      Citations: 13     Fields:    Translation:Humans
    126. Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809. PMID: 25605863.
      Citations: 44     Fields:    Translation:Humans
    127. Lamont EB, Schilsky RL, He Y, Muss H, Cohen HJ, Hurria A, Meilleur A, Kindler HL, Venook A, Lilenbaum R, Niell H, Goldberg RM, Joffe S, Alliance for Clinical Trials in Oncology. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). J Natl Cancer Inst. 2015 Jan; 107(1):336. PMID: 25432408; PMCID: PMC4271075.
      Citations: 18     Fields:    Translation:Humans
    128. Schilsky RL. Moving from evaluation to value in cancer care. Clin Cancer Res. 2015 Mar 01; 21(5):947-9. PMID: 25336697.
      Citations: 2     Fields:    Translation:Humans
    129. Hurria A, Dale W, Mooney M, Rowland JH, Ballman KV, Cohen HJ, Muss HB, Schilsky RL, Ferrell B, Extermann M, Schmader KE, Mohile SG, Cancer and Aging Research Group. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014 Aug 20; 32(24):2587-94. PMID: 25071116; PMCID: PMC4129504.
      Citations: 119     Fields:    Translation:Humans
    130. Kolacevski A, Mann JT, Hauser R, Schilsky RL. Using Big Data to Track Trends in Medical Practice. J Oncol Pract. 2015 01; 11(1):69-70. PMID: 25139800.
      Citations:    Fields:    Translation:Humans
    131. Minasian L, Rosen O, Auclair D, Rahman A, Pazdur R, Schilsky RL. Optimizing dosing of oncology drugs. Clin Pharmacol Ther. 2014 Nov; 96(5):572-9. PMID: 25105705.
      Citations: 31     Fields:    Translation:Humans
    132. Schilsky RL. Reply to F.E. Vera-Badillo et al. J Clin Oncol. 2014 Oct 01; 32(28):3198. PMID: 25092782.
      Citations:    Fields:    Translation:Humans
    133. Schilsky RL. ASCO's initiative to define value in cancer care. Am J Manag Care. 2014 Aug; 20(11 Spec No.):E1. PMID: 25618157.
      Citations:    Fields:    Translation:Humans
    134. Schilsky RL. Drivers of change in cancer care. J Oncol Pract. 2014 Sep; 10(5):315-6. PMID: 25052500.
      Citations:    Fields:    Translation:Humans
    135. Schnipper LE, Schilsky RL, Hoverman JR, Raghavan D, Lyman GH, Wollins DS, Blayney DW. Reply to L.k. Griffeth et al and J.E. Battley et al. J Clin Oncol. 2014 Sep 01; 32(25):2812-3. PMID: 25024078.
      Citations:    Fields:    Translation:Humans
    136. Innocenti F, Schilsky RL, Ramírez J, Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, Karrison T, Maitland ML, Salgia R, Ratain MJ. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014 Aug 01; 32(22):2328-34. PMID: 24958824; PMCID: PMC4105486.
      Citations: 67     Fields:    Translation:HumansCTClinical Trials
    137. Schilsky RL, Michels DL, Kearbey AH, Yu PP, Hudis CA. Building a rapid learning health care system for oncology: the regulatory framework of CancerLinQ. J Clin Oncol. 2014 Aug 01; 32(22):2373-9. PMID: 24912897.
      Citations: 45     Fields:    Translation:Humans
    138. Mayer RJ, Venook AP, Schilsky RL. Progress against GI cancer during the American Society of Clinical Oncology's first 50 years. J Clin Oncol. 2014 May 20; 32(15):1521-30. PMID: 24752046.
      Citations: 24     Fields:    Translation:Humans
    139. Schilsky RL. Implementing personalized cancer care. Nat Rev Clin Oncol. 2014 07; 11(7):432-8. PMID: 24687035.
      Citations: 37     Fields:    Translation:Humans
    140. Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014 Apr 20; 32(12):1277-80. PMID: 24638016.
      Citations: 149     Fields:    Translation:Humans
    141. Tsimberidou AM, Eggermont AM, Schilsky RL. Precision cancer medicine: the future is now, only better. Am Soc Clin Oncol Educ Book. 2014; 61-9. PMID: 24857061.
      Citations: 20     Fields:    Translation:Humans
    142. Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, Kwekkeboom D, Lau WY, Klersy C, Davidson B, Siegler M, Caplin M, Solcia E, Schilsky R, Working Group on Neuroendocrine Liver Metastases, Vilgrain V. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014 Jan; 15(1):e8-21. PMID: 24384494.
      Citations: 179     Fields:    Translation:HumansCells
    143. Schnipper LE, Lyman GH, Blayney DW, Hoverman JR, Raghavan D, Wollins DS, Schilsky RL. American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol. 2013 Dec 01; 31(34):4362-70. PMID: 24170249.
      Citations: 47     Fields:    Translation:Humans
    144. Schilsky RL. Wither the cooperative groups? J Clin Oncol. 2014 Jan 20; 32(3):251-4. PMID: 24043728.
      Citations: 3     Fields:    Translation:Humans
    145. Schilsky RL. Highlights from the 2013 WIN Symposium: personalised cancer therapy from innovation to implementation. Ecancermedicalscience. 2013; 7:344. PMID: 24009643; PMCID: PMC3756641.
      Citations:    
    146. Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DG, McCormack R, Newcomer L, Pothier K, Ransohoff D, Schilsky RL, Sigal E, Taube SE, Tunis SR. Breaking a vicious cycle. Sci Transl Med. 2013 Jul 31; 5(196):196cm6. PMID: 23903752.
      Citations: 44     Fields:    Translation:HumansAnimals
    147. Sharma MR, Karrison TG, Kell B, Wu K, Turcich M, Geary D, Kang SP, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen EE. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67. PMID: 23553850; PMCID: PMC3674138.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    148. Wilson WH, Schenkein DP, Jernigan CL, Woodcock J, Schilsky RL. Reevaluating the accelerated approval process for oncology drugs. Clin Cancer Res. 2013 Jun 01; 19(11):2804-9. PMID: 23553847.
      Citations: 6     Fields:    Translation:Humans
    149. Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, Frankel W, Clark-Langone K, Millward C, Shak S, Goldberg RM, Mahmoud NN, Warren RS, Schilsky RL, Bertagnolli MM. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013 May 10; 31(14):1775-81. PMID: 23530100; PMCID: PMC3641698.
      Citations: 67     Fields:    Translation:HumansCells
    150. Conti RM, Bernstein AC, Villaflor VM, Schilsky RL, Rosenthal MB, Bach PB. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol. 2013 Mar 20; 31(9):1134-9. PMID: 23423747; PMCID: PMC3595423.
      Citations: 49     Fields:    Translation:Humans
    151. Schilsky RL. Publicly funded clinical trials and the future of cancer care. Oncologist. 2013; 18(2):232-8. PMID: 23363807; PMCID: PMC3579608.
      Citations: 11     Fields:    Translation:Humans
    152. Tsimberidou AM, Ringborg U, Schilsky RL. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. Am Soc Clin Oncol Educ Book. 2013; 118-25. PMID: 23714475.
      Citations: 13     Fields:    Translation:HumansPHPublic Health
    153. Hahn OM, Schilsky RL. Randomized controlled trials and comparative effectiveness research. J Clin Oncol. 2012 Dec 01; 30(34):4194-201. PMID: 23071239.
      Citations: 12     Fields:    Translation:Humans
    154. Schilsky RL. Targeted therapy for cancer: asking the right questions. Oncology (Williston Park). 2012 Oct; 26(10):947-9. PMID: 23176006.
      Citations:    Fields:    Translation:Humans
    155. Schilsky RL. Scarcity of vital oncology drugs: finding long-term solutions. Clin Adv Hematol Oncol. 2012 Sep; 10(9):597-9. PMID: 23073126.
      Citations:    Fields:    
    156. Schilsky RL. Advanced clinical trials for China. Chin Clin Oncol. 2012 Sep; 1(1):3. PMID: 25842061.
      Citations:    Fields:    
    157. Dale W, Mohile SG, Eldadah BA, Trimble EL, Schilsky RL, Cohen HJ, Muss HB, Schmader KE, Ferrell B, Extermann M, Nayfield SG, Hurria A, Cancer and Aging Research Group. Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J Natl Cancer Inst. 2012 Apr 18; 104(8):581-9. PMID: 22457474; PMCID: PMC3328422.
      Citations: 54     Fields:    Translation:Humans
    158. Schilsky RL, Doroshow JH, Leblanc M, Conley BA. Development and use of integral assays in clinical trials. Clin Cancer Res. 2012 Mar 15; 18(6):1540-6. PMID: 22422406; PMCID: PMC3307146.
      Citations: 15     Fields:    Translation:Humans
    159. Mendelsohn J, Ringborg U, Schilsky RL. Personalized cancer medicine - a strategy to counteract an increasing cancer challenge. Mol Oncol. 2012 Apr; 6(2):109-10. PMID: 22507633; PMCID: PMC5528371.
      Citations: 6     Fields:    Translation:Humans
    160. Katz ML, Archer LE, Peppercorn JM, Kereakoglow S, Collyar DE, Burstein HJ, Schilsky RL, Partridge AH. Patient advocates' role in clinical trials: perspectives from Cancer and Leukemia Group B investigators and advocates. Cancer. 2012 Oct 01; 118(19):4801-5. PMID: 22392584.
      Citations: 17     Fields:    Translation:Humans
    161. Sharma MR, Schilsky RL. Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol. 2011 Dec 06; 9(4):208-14. PMID: 22143142.
      Citations: 22     Fields:    Translation:Humans
    162. Innocenti F, Owzar K, Cox NL, Evans P, Kubo M, Zembutsu H, Jiang C, Hollis D, Mushiroda T, Li L, Friedman P, Wang L, Glubb D, Hurwitz H, Giacomini KM, McLeod HL, Goldberg RM, Schilsky RL, Kindler HL, Nakamura Y, Ratain MJ. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res. 2012 Jan 15; 18(2):577-84. PMID: 22142827; PMCID: PMC3412624.
      Citations: 46     Fields:    Translation:Humans
    163. Ambrose LF, Freedman J, Buetow K, Friend S, Schilsky RL. Using patient-initiated study participation in the development of evidence for personalized cancer therapy. Clin Cancer Res. 2011 Nov 01; 17(21):6651-7. PMID: 22046027.
      Citations: 2     Fields:    Translation:Humans
    164. Schilsky RL. Drug approval challenges in the age of personalized cancer treatment. Per Med. 2011 Nov; 8(6):633-640. PMID: 29776208.
      Citations:    Fields:    
    165. Maitland ML, Schilsky RL. Clinical trials in the era of personalized oncology. CA Cancer J Clin. 2011 Nov-Dec; 61(6):365-81. PMID: 22034206; PMCID: PMC3218227.
      Citations: 31     Fields:    Translation:Humans
    166. Rimm DL, Nielsen TO, Jewell SD, Rohrer DC, Broadwater G, Waldman F, Mitchell KA, Singh B, Tsongalis GJ, Frankel WL, Magliocco AM, Lara JF, Hsi ED, Bleiweiss IJ, Badve SS, Chen B, Ravdin PM, Schilsky RL, Thor A, Berry DA, Cancer and Leukemia Group B Pathology Committee. Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. J Clin Oncol. 2011 Jun 01; 29(16):2282-90. PMID: 21519016; PMCID: PMC3107745.
      Citations: 16     Fields:    Translation:Humans
    167. Schilsky RL, Crowther M. Update in hematology and oncology: evidence published in 2010. Ann Intern Med. 2011 Apr 05; 154(7):487-94. PMID: 21464351.
      Citations:    Fields:    Translation:Humans
    168. Schilsky RL. Tumor heterogeneity as the foundation of personalized cancer treatment. Semin Oncol. 2011 Apr; 38(2):171-2. PMID: 21421107.
      Citations: 2     Fields:    Translation:Humans
    169. Schilsky RL. Accrual to cancer clinical trials in the era of molecular medicine. Sci Transl Med. 2011 Mar 23; 3(75):75cm9. PMID: 21430267.
      Citations: 8     Fields:    Translation:Humans
    170. Mendelsohn J, Tursz T, Schilsky RL, Lazar V. WIN Consortium--challenges and advances. Nat Rev Clin Oncol. 2011 Mar; 8(3):133-4. PMID: 21364685.
      Citations: 8     Fields:    Translation:Humans
    171. Cohen EE, Schilsky RL. The next phase of chemoprevention research. Cancer Prev Res (Phila). 2011 Mar; 4(3):293-5. PMID: 21372026.
      Citations:    Fields:    Translation:Humans
    172. Shapiro CL, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, Sikov W, Winer E, Burstein HJ, Hudis C, Isaacs C, Schilsky R, Paskett E. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011 Mar; 47(5):683-9. PMID: 21324674; PMCID: PMC4211594.
      Citations: 32     Fields:    Translation:Humans
    173. Sharma MR, Schilsky RL. GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy. Nat Rev Clin Oncol. 2011 Feb; 8(2):70-2. PMID: 21278772.
      Citations: 10     Fields:    Translation:Humans
    174. McClellan M, Benner J, Schilsky R, Epstein D, Woosley R, Friend S, Sidransky D, Geoghegan C, Kessler D. An accelerated pathway for targeted cancer therapies. Nat Rev Drug Discov. 2011 02; 10(2):79-80. PMID: 21283090.
      Citations: 12     Fields:    Translation:HumansAnimals
    175. O'Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii-Saab T, Pluard T, Douglas K, Abou-Alfa GK, Kindler HL, Schilsky RL, Goldberg RM, Cancer and Leukemia Group B. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist. 2010; 15(12):1310-9. PMID: 21148613; PMCID: PMC3227926.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    176. Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, Nelson SA, Weinshilboum RM, Ratain MJ, McLeod HL, Epstein RS, Ginsburg GS, Schilsky RL, Liu G, Flockhart DA, Ulrich CM, Davis RL, Lesko LJ, Zineh I, Randhawa G, Ambrosone CB, Relling MV, Rothman N, Xie H, Spitz MR, Ballard-Barbash R, Doroshow JH, Minasian LM. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705. PMID: 20944079; PMCID: PMC2982809.
      Citations: 20     Fields:    Translation:HumansAnimals
    177. Kaiser LD, Melemed AS, Preston AJ, Chaudri Ross HA, Niedzwiecki D, Fyfe GA, Gough JM, Bushnell WD, Stephens CL, Mace MK, Abrams JS, Schilsky RL. Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications. J Clin Oncol. 2010 Dec 01; 28(34):5046-53. PMID: 20921453; PMCID: PMC3018355.
      Citations: 5     Fields:    Translation:Humans
    178. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010 Aug 01; 28(22):3617-22. PMID: 20606091; PMCID: PMC2917317.
      Citations: 378     Fields:    Translation:HumansCTClinical Trials
    179. Gangadhar T, Schilsky RL. Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol. 2010 Jun; 7(6):318-25. PMID: 20440283.
      Citations: 32     Fields:    Translation:Humans
    180. Schilsky RL. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov. 2010 05; 9(5):363-6. PMID: 20431568.
      Citations: 114     Fields:    Translation:Humans
    181. Potti A, Schilsky RL, Nevins JR. Refocusing the war on cancer: the critical role of personalized treatment. Sci Transl Med. 2010 Apr 21; 2(28):28cm13. PMID: 20410527.
      Citations: 11     Fields:    Translation:HumansAnimals
    182. Peppercorn J, Shapira I, Collyar D, Deshields T, Lin N, Krop I, Grunwald H, Friedman P, Partridge AH, Schilsky RL, Bertagnolli MM. Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol. 2010 May 20; 28(15):2635-40. PMID: 20406927; PMCID: PMC5596502.
      Citations: 30     Fields:    Translation:HumansPHPublic Health
    183. Menter DG, Schilsky RL, DuBois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res. 2010 Mar 01; 16(5):1384-90. PMID: 20179228; PMCID: PMC4307592.
      Citations: 77     Fields:    Translation:HumansAnimalsCells
    184. Schilsky RL, Allen J, Benner J, Sigal E, McClellan M. Commentary: tackling the challenges of developing targeted therapies for cancer. Oncologist. 2010; 15(5):484-7. PMID: 20489184; PMCID: PMC3227984.
      Citations: 6     Fields:    Translation:Humans
    185. Abrams J, Erwin R, Fyfe G, Schilsky RL. Data submission standards and evidence requirements. Oncologist. 2010; 15(5):488-91. PMID: 20489185; PMCID: PMC3227973.
      Citations:    Fields:    Translation:Humans
    186. Haller DG, Sargent DJ, Tabernero J, Matheson A, Schilsky RL, de Gramont A. Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program. J Clin Oncol. 2010 Feb 01; 28(4):527-30. PMID: 19841311.
      Citations: 7     Fields:    Translation:Humans
    187. Innocenti F, Schilsky RL. Translating the cancer genome into clinically useful tools and strategies. Dis Model Mech. 2009 Sep-Oct; 2(9-10):426-9. PMID: 19726797.
      Citations: 6     Fields:    Translation:Humans
    188. Goss E, Link MP, Bruinooge SS, Lawrence TS, Tepper JE, Runowicz CD, Schilsky RL. The impact of the privacy rule on cancer research: variations in attitudes and application of regulatory standards. J Clin Oncol. 2009 Aug 20; 27(24):4014-20. PMID: 19620480.
      Citations: 2     Fields:    Translation:Humans
    189. Schilsky RL. Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. J Clin Oncol. 2009 Aug 10; 27(23):3725-30. PMID: 19581526.
      Citations: 14     Fields:    Translation:Humans
    190. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009 Apr 20; 27(12):2091-6. PMID: 19188670.
      Citations: 489     Fields:    Translation:Humans
    191. Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, Sawaya R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL, American Society of Clinical Oncology. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2009 Feb 10; 27(5):812-26. PMID: 19103723; PMCID: PMC2645086.
      Citations: 41     Fields:    Translation:Humans
    192. Schilsky RL. Join ASCO in Welcoming Dr John Cox As Editor-in-Chief. J Oncol Pract. 2008 Nov; 4(6):266. PMID: 20856754; PMCID: PMC2793905.
      Citations:    Fields:    
    193. Perry MC, Comis RL, Schilsky RL. Introduction: contributions of the cooperative groups. Semin Oncol. 2008 Oct; 35(5):459. PMID: 18929144.
      Citations:    Fields:    Translation:Humans
    194. Green MR, George SL, Schilsky RL, Cancer and Leukemia Group B. Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B. Semin Oncol. 2008 Oct; 35(5):470-83. PMID: 18929146; PMCID: PMC3886682.
      Citations: 1     Fields:    Translation:Humans
    195. Strauss GM, Herndon JE, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008 Nov 01; 26(31):5043-51. PMID: 18809614; PMCID: PMC2652093.
      Citations: 334     Fields:    Translation:Humans
    196. Schilsky RL, Gordon G, Gilmer TM, Courtneidge SA, Matrisian LM, Grad O, Nelson WG, Translational Research Working Group. The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics). Clin Cancer Res. 2008 Sep 15; 14(18):5685-91. PMID: 18794076; PMCID: PMC3978169.
      Citations: 3     Fields:    Translation:Humans
    197. Schilsky RL. How not to treat cancer. Lancet Oncol. 2008 Jun; 9(6):504-5. PMID: 18510981.
      Citations: 1     Fields:    Translation:Humans
    198. Bressler LR, Schilsky RL. Collaboration between cooperative groups and industry. J Oncol Pract. 2008 May; 4(3):140-1. PMID: 20856620; PMCID: PMC2793998.
      Citations: 3     Fields:    
    199. Zon R, Meropol NJ, Catalano RB, Schilsky RL. American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol. 2008 May 20; 26(15):2562-7. PMID: 18390967.
      Citations: 33     Fields:    Translation:Humans
    200. Lamont EB, Herndon JE, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA, Cancer and Leukemia Group B. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Med Care. 2008 Mar; 46(3):303-8. PMID: 18388845; PMCID: PMC4158032.
      Citations: 13     Fields:    Translation:Humans
    201. Daugherty CK, Ratain MJ, Emanuel EJ, Farrell AT, Schilsky RL. Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol. 2008 Mar 10; 26(8):1371-8. PMID: 18227527.
      Citations: 16     Fields:    Translation:Humans
    202. Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner J, Demetri GD, Curran W, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey S, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Davidson NE, Schilsky RL, Lichter AS, American Society of Clinical Oncology. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2008 Jan 10; 26(2):313-25. PMID: 18086794.
      Citations: 27     Fields:    Translation:Humans
    203. Posner MC, Niedzwiecki D, Venook AP, Hollis DR, Kindler HL, Martin EW, Schilsky RL, Goldberg RM, Mayer RJ. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann Surg Oncol. 2008 Jan; 15(1):158-64. PMID: 18008108.
      Citations: 6     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    204. Young RC, Friedman MA, Schilsky RL, Sigal EV. Drug safety and drug efficacy: two sides of the same coin. Clin Cancer Res. 2007 May 01; 13(9):2533-4. PMID: 17473179.
      Citations: 3     Fields:    Translation:Humans
    205. Kelloff GJ, Sullivan DM, Wilson W, Cheson B, Juweid M, Mills GQ, Zelenetz AD, Horning SJ, Weber W, Sargent DJ, Dodd L, Korn E, Armitage J, Schilsky R, Christian M, O'connor OA, Wang SJ, Farrell AT, Pazdur R, Graham M, Wahl RL, Larson SM, Kostakoglu L, Daube-Witherspoon M, Gastonis C, Siegel BA, Shankar LK, Lee DB, Higley HR, Sigman CC, Carucci D, Timko D, deGennaro LJ, Sigal E, Barker A, Woodcock J. FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol. 2007 Mar; 14(3):330-9. PMID: 17307666.
      Citations: 9     Fields:    Translation:Humans
    206. Yong WP, Desai AA, Innocenti F, Ramirez J, Shepard D, Kobayashi K, House L, Fleming GF, Vogelzang NJ, Schilsky RL, Ratain MJ. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2007 Nov; 60(6):811-9. PMID: 17308893.
      Citations: 10     Fields:    Translation:Humans
    207. Schilsky RL. Target practice: oncology drug development in the era of genomic medicine. Clin Trials. 2007; 4(2):163-6; discussion 173-7. PMID: 17456516.
      Citations: 5     Fields:    Translation:Humans
    208. Mauer AM, Rich ES, Schilsky RL. The role of cooperative groups in cancer clinical trials. Cancer Treat Res. 2007; 132:111-29. PMID: 17305018.
      Citations: 6     Fields:    Translation:Humans
    209. Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ, Eisenberg BL, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Reaman GH, Sawaya R, Schilsky RL, Schuchter LM, Sweetenham JW, Vahdat LT, Winn RJ, American Society of Clinical Oncology. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2007 Jan 01; 25(1):146-62. PMID: 17158528.
      Citations: 24     Fields:    Translation:Humans
    210. Dilts DM, Sandler AB, Baker M, Cheng SK, George SL, Karas KS, McGuire S, Menon GS, Reusch J, Sawyer D, Scoggins M, Wu A, Zhou K, Schilsky RL, Case of Cancer and Leukemia Group B. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. J Clin Oncol. 2006 Oct 01; 24(28):4553-7. PMID: 17008694.
      Citations: 33     Fields:    Translation:Humans
    211. Lamont EB, Herndon JE, Weeks JC, Henderson IC, Earle CC, Schilsky RL, Christakis NA, Cancer and Leukemia Group B. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst. 2006 Sep 20; 98(18):1335-8. PMID: 16985253; PMCID: PMC4158031.
      Citations: 49     Fields:    Translation:Humans
    212. Bial AK, Schilsky RL, Sachs GA. Evaluation of cognition in cancer patients: special focus on the elderly. Crit Rev Oncol Hematol. 2006 Dec; 60(3):242-55. PMID: 16860995.
      Citations: 2     Fields:    Translation:Humans
    213. Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Nelson H, Whittom R, Hantel A, Schilsky RL, Fuchs CS. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006 Aug 01; 24(22):3535-41. PMID: 16822843.
      Citations: 277     Fields:    Translation:Humans
    214. Schilsky RL, McIntyre OR, Holland JF, Frei E. A concise history of the cancer and leukemia group B. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3553s-5s. PMID: 16740784.
      Citations: 12     Fields:    Translation:Humans
    215. Ratain MJ, Miller AA, McLeod HL, Venook AP, Egorin MJ, Schilsky RL. The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3612s-6s. PMID: 16740794.
      Citations: 9     Fields:    Translation:Humans
    216. Friberg G, Schilsky RL. Is oral tegafur with leucovorin equivalent to intravenous 5-fluorouracil and leucovorin in colorectal cancer? Nat Clin Pract Oncol. 2006 May; 3(5):240-1. PMID: 16682999.
      Citations:    Fields:    
    217. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006 Feb; 33(1):15-49. PMID: 16473643.
      Citations: 126     Fields:    Translation:HumansAnimals
    218. Lamont EB, Herndon JE, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005 Jul 20; 97(14):1080-3. PMID: 16030306.
      Citations: 37     Fields:    Translation:Humans
    219. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O'shaughnessy J, Guyton KZ, Mankoff DA, Shankar L, Larson SM, Sigman CC, Schilsky RL, Sullivan DC. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005 Apr 15; 11(8):2785-808. PMID: 15837727.
      Citations: 233     Fields:    
    220. Desai AA, Schilsky RL, Young A, Janisch L, Stadler WM, Vogelzang NJ, Cadden S, Wright JA, Ratain MJ. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol. 2005 Jun; 16(6):958-65. PMID: 15824081.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    221. Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG, Schuster MW, Marks LB, Cirrincione C, Norton L, Henderson IC, Schilsky RL, Hurd DD. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005 Apr 01; 23(10):2191-200. PMID: 15767638.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    222. Schilsky RL. First-line treatment options for patients with metastatic colorectal cancer. Nat Clin Pract Oncol. 2004 Dec; 1(2):70-1. PMID: 16264820.
      Citations:    Fields:    Translation:Humans
    223. Innocenti F, Undevia SD, Mani S, Schilsky RL, Vogelzang NJ, Prado M, Ratain MJ, Ramírez J. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther. 2004 Nov; 76(5):490-502. PMID: 15536463.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    224. Undevia SD, Kindler HL, Janisch L, Olson SC, Schilsky RL, Vogelzang NJ, Kimmel KA, Macek TA, Ratain MJ. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol. 2004 Nov; 15(11):1705-11. PMID: 15520075.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    225. Goldberg RM, Venook AP, Schilsky RL. Cetuximab in the treatment of colorectal cancer. Clin Adv Hematol Oncol. 2004 Nov; 2(11):1-10; quiz 11-12. PMID: 16170891.
      Citations:    Fields:    Translation:Humans
    226. Helft PR, Schilsky RL, Hoke FJ, Williams D, Kindler HL, Sprague E, DeWitte M, Martino HK, Erickson J, Pandite L, Russo M, Lambert JM, Howard M, Ratain MJ. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 01; 10(13):4363-8. PMID: 15240523.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    227. Taube SE, Gion M, Schilsky RL. 3rd EORTC-NCI International Meeting on Cancer Molecular Markers: From Discovery to Clinical Practice. Expert Rev Mol Diagn. 2004 Jul; 4(4):431-3. PMID: 15225090.
      Citations: 1     Fields:    Translation:Humans
    228. Kelloff GJ, Schilsky RL, Alberts DS, Day RW, Guyton KZ, Pearce HL, Peck JC, Phillips R, Sigman CC. Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs. Clin Cancer Res. 2004 Jun 01; 10(11):3908-18. PMID: 15173100.
      Citations: 12     Fields:    Translation:Humans
    229. Kelloff GJ, Bast RC, Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Vande Woude GF. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res. 2004 Jun 01; 10(11):3881-4. PMID: 15173097.
      Citations: 14     Fields:    Translation:HumansAnimals
    230. Partridge AH, Hackett N, Blood E, Gelman R, Joffe S, Bauer-Wu S, Knudsen K, Emmons K, Collyar D, Schilsky RL, Winer EP. Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants. J Natl Cancer Inst. 2004 Apr 21; 96(8):629-32. PMID: 15100341.
      Citations: 31     Fields:    Translation:Humans
    231. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL, Cancer and Leukemia Group B. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res. 2004 Apr 15; 10(8):2584-6. PMID: 15102658.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    232. Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004 Mar 22; 90(6):1190-7. PMID: 15026800; PMCID: PMC2409640.
      Citations: 103     Fields:    Translation:HumansCTClinical Trials
    233. Schilsky RL. Are targeted therapies really targeted? Clin Adv Hematol Oncol. 2003 Dec; 1(12):722-3. PMID: 16258475.
      Citations:    Fields:    Translation:Humans
    234. Schilsky RL. Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients? J Clin Oncol. 2003 Oct 15; 21(20):3718-20. PMID: 12963701.
      Citations: 2     Fields:    Translation:Humans
    235. Fleming GF, Schilsky RL, Schumm LP, Meyerson A, Hong AM, Vogelzang NJ, Ratain MJ. Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Ann Oncol. 2003 Jul; 14(7):1142-7. PMID: 12853359.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    236. Sawyer MB, Ratain MJ, Bertucci D, Smith RP, Schilsky RL, Vogelzang NJ, Shulman K, Douglass EC, Fleming GF. Phase I study of an oral formulation of ZD9331 administered daily for 28 days. J Clin Oncol. 2003 May 01; 21(9):1859-65. PMID: 12721264.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    237. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):976-83. PMID: 12637460.
      Citations: 321     Fields:    Translation:HumansCTClinical Trials
    238. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003 Mar 06; 348(10):883-90. PMID: 12621132.
      Citations: 371     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    239. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15; 21(8):1431-9. PMID: 12668651.
      Citations: 405     Fields:    Translation:HumansCTClinical Trials
    240. Fleming GF, Meropol NJ, Rosner GL, Hollis DR, Carson WE, Caligiuri M, Mortimer J, Tkaczuk K, Parihar R, Schilsky RL, Ratain MJ. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27. PMID: 12473581.
      Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
    241. Maung K, Lee D, DeGrendele HC, Schilsky R, Chu E, Jain VK, Copur S. Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002. Clin Colorectal Cancer. 2002 Nov; 2(3):140-5. PMID: 12482329.
      Citations:    Fields:    Translation:Humans
    242. Schilsky RL, Taube SE, Schilsky RL, Taube SE. Tumor markers as clinical cancer tests--are we there yet? Semin Oncol. 2002 Jun; 29(3):211-2. PMID: 12063673.
      Citations: 10     Fields:    Translation:Humans
    243. Schilsky RL, Dressler LM, Bucci D, Monovich L, Jewell S, Suster S, Caligiuri MA, Kantoff PW, Compton C. Cooperative group tissue banks as research resources: the cancer and leukemia group B tissue repositories. Clin Cancer Res. 2002 May; 8(5):943-8. PMID: 12006505.
      Citations: 2     Fields:    Translation:Humans
    244. Schilsky RL, Schilsky RL. Inhibiting 5-fluorouracil breakdown: a broken down approach to 5-fluorouracil modulation. Clin Colorectal Cancer. 2002 May; 2(1):51-2. PMID: 12453336.
      Citations: 2     Fields:    Translation:Humans
    245. Schilsky RL, Schilsky RL. End points in cancer clinical trials and the drug approval process. Clin Cancer Res. 2002 Apr; 8(4):935-8. PMID: 11948095.
      Citations: 15     Fields:    Translation:Humans
    246. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Rosso R, Rougier P, Schilsky RL, Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Rosso R, Rougier P, Schilsky RL, Capecitabine Colorectal Cancer Study Group. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002 Apr; 13(4):566-75. PMID: 12056707.
      Citations: 126     Fields:    Translation:HumansCTClinical Trials
    247. Schilsky RL, Levin J, West WH, Wong A, Colwell B, Thirlwell MP, Ansari RH, Bell WN, White RL, Yates BB, McGuirt PV, Pazdur R. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol. 2002 Mar 15; 20(6):1519-26. PMID: 11896100.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    248. Lamont EB, Lauderdale DS, Schilsky RL, Christakis NA. Construct validity of medicare chemotherapy claims: the case of 5FU. Med Care. 2002 Mar; 40(3):201-11. PMID: 11880793.
      Citations: 27     Fields:    Translation:Humans
    249. Shepard DR, Mani S, Kastrissios H, Learned-Coughlin S, Smith D, Ertel P, Magnum S, Janisch L, Fleming GF, Schilsky RL, Ratain MJ, Shepard DR, Mani S, Kastrissios H, Learned-Coughlin S, Smith D, Ertel P, Magnum S, Janisch L, Fleming GF, Schilsky RL, Ratain MJ. Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. Cancer Chemother Pharmacol. 2002 May; 49(5):398-402. PMID: 11976834.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    250. Schilsky RL, Bertucci D, Vogelzang NJ, Kindler HL, Ratain MJ. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002 Jan 15; 20(2):582-7. PMID: 11786589.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    251. Dolan ME, Schilsky RL. Silence is golden: gene hypermethylation and survival in large-cell lymphoma. J Natl Cancer Inst. 2002 Jan 02; 94(1):6-7. PMID: 11773269.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    252. Iyer L, Das S, Janisch L, Wen M, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ, Ramírez J. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2(1):43-7. PMID: 11990381.
      Citations: 178     Fields:    Translation:Humans
    253. Blanke CD, Shultz J, Cox J, Modiano M, Isaacs R, Kasimis B, Schilsky R, Fleagle J, Moore M, Kemeny N, Carlin D, Hammershaimb L, Haller D. A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer. Ann Oncol. 2002 Jan; 13(1):87-91. PMID: 11863117.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    254. Lichtman SM, Petroni G, Schilsky RL, Johnson JL, Perri RT, Niedzwiecki D, Sklar J, Barcos M, Peterson BA. High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150. Leuk Lymphoma. 2001 Nov-Dec; 42(6):1255-64. PMID: 11911406.
      Citations:    Fields:    Translation:Humans
    255. Mani S, Vogelzang NJ, Bertucci D, Stadler WM, Schilsky RL, Ratain MJ. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001 Sep 15; 92(6):1567-76. PMID: 11745236.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    256. Eng C, Kindler HL, Schilsky RL, Eng C, Kindler HL, Schilsky RL. Oral fluoropyrimidine treatment of colorectal cancer. Clin Colorectal Cancer. 2001 Aug; 1(2):95-103. PMID: 12445367.
      Citations: 3     Fields:    Translation:Humans
    257. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med. 2001 Jul 12; 345(2):144-5; author reply 146. PMID: 11450666.
      Citations: 34     Fields:    Translation:Humans
    258. Meropol NJ, Niedzwiecki D, Hollis D, Schilsky RL, Mayer RJ, Cancer and Leukemia Group B. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Cancer. 2001 Apr 01; 91(7):1256-63. PMID: 11283924.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    259. Ewesuedo RB, Iyer L, Das S, Koenig A, Mani S, Vogelzang NJ, Schilsky RL, Brenckman W, Ratain MJ. Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer. J Clin Oncol. 2001 Apr 01; 19(7):2084-90. PMID: 11283142.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    260. Goh BC, Ratain MJ, Bertucci D, Smith R, Mani S, Vogelzang NJ, Schilsky RL, Hutchison M, Smith M, Averbuch S, Douglass E. Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J Clin Oncol. 2001 Mar 01; 19(5):1476-84. PMID: 11230494.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    261. Williams SF, Schilsky RL. Antineoplastic drugs administered during pregnancy. Semin Oncol. 2000 Dec; 27(6):618-22. PMID: 11130468.
      Citations: 3     Fields:    Translation:Humans
    262. Schilsky RL. Pharmacology and clinical status of capecitabine. Oncology (Williston Park). 2000 Sep; 14(9):1297-306; discussion 1309-11. PMID: 11033828.
      Citations: 8     Fields:    Translation:HumansAnimals
    263. Mani S, Hochster H, Beck T, Chevlen EM, O'Rourke MA, Weaver CH, Bell WN, White R, McGuirt C, Levin J, Hohneker J, Schilsky RL, Lokich J. Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2000 Aug; 18(15):2894-901. PMID: 10920138.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    264. Schilsky RL, Dolan ME, Bertucci D, Ewesuedo RB, Vogelzang NJ, Mani S, Wilson LR, Ratain MJ. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res. 2000 Aug; 6(8):3025-31. PMID: 10955780.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    265. Schilsky RL, Kindler HL. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul; 9(7):1635-49. PMID: 11060767.
      Citations: 5     Fields:    Translation:HumansAnimals
    266. Schilsky RL, Bukowski R, Burris H, Hochster H, O'Rourke M, Wall JG, Mani S, Bonny T, Levin J, Hohneker J. A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. Ann Oncol. 2000 Apr; 11(4):415-20. PMID: 10847459.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    267. Lamont EB, Schilsky RL. The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res. 1999 Sep; 5(9):2289-96. PMID: 10499595.
      Citations: 17     Fields:    Translation:Humans
    268. Costanza ME, Weiss RB, Henderson IC, Norton L, Berry DA, Cirrincione C, Winer E, Wood WC, Frei E, McIntyre OR, Schilsky RL. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. J Clin Oncol. 1999 May; 17(5):1397-406. PMID: 10334524.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    269. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer. 1999 Mar 15; 85(6):1261-8. PMID: 10189130.
      Citations: 59     Fields:    Translation:Humans
    270. Schilsky RL. Immunotherapy for colorectal cancer. Curr Oncol Rep. 1999; 1(2):147-8. PMID: 11122811.
      Citations:    Fields:    Translation:Humans
    271. Mani S, Sciortino D, Samuels B, Arrietta R, Schilsky RL, Vokes EE, Benner S. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Invest New Drugs. 1999; 17(1):97-101. PMID: 10555128.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    272. Lilenbaum RC, Miller AA, Batist G, Bernard S, Hollis DR, Rosner GL, Egorin MJ, Schilsky RL, Ratain MJ. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study. J Clin Oncol. 1998 Oct; 16(10):3302-9. PMID: 9779705.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    273. Schilsky RL. Biochemical and clinical pharmacology of 5-fluorouracil. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):13-8. PMID: 9830619.
      Citations: 16     Fields:    Translation:Humans
    274. Mani S, Kugler JW, Sciortino DF, Garcia JC, Ansari RH, Humerickhouse R, Michelassi F, Posner MC, Shulman KL, Schilsky RL, List M, Vokes EE, Benner S. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study. Ann Oncol. 1998 Sep; 9(9):1035-7. PMID: 9818081.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    275. Dolan ME, Roy SK, Fasanmade AA, Paras PR, Schilsky RL, Ratain MJ. O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol. 1998 May; 16(5):1803-10. PMID: 9586894.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    276. Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM, Schilsky RL. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol. 1998 May; 16(5):1811-9. PMID: 9586895.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    277. Schilsky RL, Hohneker J, Ratain MJ, Janisch L, Smetzer L, Lucas VS, Khor SP, Diasio R, Von Hoff DD, Burris HA. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol. 1998 Apr; 16(4):1450-7. PMID: 9552051.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    278. Vogelzang NJ, Mani S, Schilsky RL, Ansari RH, Taber D, Rhinehart SN, Garcia JC, Meyer SC, Mick R, Brockstein BE, Stadler WM, Ratain MJ, Vokes EE. Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Clin Cancer Res. 1998 Apr; 4(4):929-34. PMID: 9563886.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    279. Mani S, Iyer L, Janisch L, Wang X, Fleming GF, Schilsky RL, Ratain MJ. Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol. 1998; 42(1):84-7. PMID: 9619763.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    280. Mani S, Kugler JW, Knost JA, Sciortino DF, Gibbons J, Garcia JC, Ansari RH, Schilsky RL, Vokes EE. Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer. Invest New Drugs. 1998-1999; 16(3):275-8. PMID: 10360609.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    281. Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R, Fisher RI, Peterson BA, Oken MM. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol. 1998 Jan; 16(1):19-26. PMID: 9440718.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    282. Samuels BL, Hollis DR, Rosner GL, Trump DL, Shapiro CL, Vogelzang NJ, Schilsky RL. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. Clin Cancer Res. 1997 Nov; 3(11):1977-84. PMID: 9815587.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    283. Chen L, Haraf D, Brachman D, Vokes E, Schilsky R. Concomitant 5-FU, hydroxyurea and cisplatin with external beam radiation therapy for locally advanced pancreatic cancer. Oncol Rep. 1997 Sep-Oct; 4(5):877-81. PMID: 21590158.
      Citations:    Fields:    
    284. Cohen AM, Kelsen D, Saltz L, Minsky BD, Nelson H, Farouk R, Gunderson LL, Michelassi F, Arenas RB, Schilsky RL, Willet CG. Adjuvant therapy for colorectal cancer. Curr Probl Surg. 1997 Aug; 34(8):601-76. PMID: 9251585.
      Citations: 8     Fields:    Translation:Humans
    285. Ratain MJ, Skoog LA, O'Brien SM, Cooper N, Schilsky RL, Vogelzang NJ, Gerber M, Narang PK, Nicol SJ. Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule. Ann Oncol. 1997 Aug; 8(8):807-9. PMID: 9332692.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    286. Miller AA, Rosner GL, Ratain MJ, Hollis DR, Green MR, Schilsky RL. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062). Clin Cancer Res. 1997 May; 3(5):719-25. PMID: 9815741.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    287. Fleming GF, O'Brien SM, Hoffman PC, Vokes EE, Vogelzang NJ, Schilsky RL, Waggoner SE, Ratain MJ. Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin. Cancer Chemother Pharmacol. 1997; 39(3):227-32. PMID: 8996525.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    288. Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, Henderson IC, Schilsky RL. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol. 1996 Nov; 14(11):3000-8. PMID: 8918498.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    289. Greco FA, Figlin R, York M, Einhorn L, Schilsky R, Marshall EM, Buys SS, Froimtchuk MJ, Schuller J, Schuchter L, Buyse M, Ritter L, Man A, Yap AK. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol. 1996 Oct; 14(10):2674-81. PMID: 8874326.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    290. Miller AA, Lilenbaum RC, Lynch TJ, Rosner GL, Ratain MJ, Green MR, Schilsky RL. Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. J Clin Oncol. 1996 Jun; 14(6):1964-5. PMID: 8656268.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    291. Mick R, Vokes EE, Lestingi TM, Gray-Stern W, Fleming GF, Schilsky RL, Ratain MJ. Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1996 Mar; 59(3):349-59. PMID: 8653998.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    292. Ratain MJ, Mick R, Janisch L, Berezin F, Schilsky RL, Vogelzang NJ, Kut M. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics. 1996 Feb; 6(1):93-101. PMID: 8845865.
      Citations: 8     Fields:    Translation:HumansCells
    293. Schilsky RL. Methotrexate: an effective agent for treating cancer and building careers. The polyglutamate era. Stem Cells. 1996 Jan; 14(1):29-32. PMID: 8820948.
      Citations: 4     Fields:    Translation:HumansAnimals
    294. Shulman K, Schilsky RL. Adjuvant therapy of colon cancer. Semin Oncol. 1995 Dec; 22(6):600-10. PMID: 8539635.
      Citations: 1     Fields:    Translation:Humans
    295. Lilenbaum RC, Ratain MJ, Miller AA, Hargis JB, Hollis DR, Rosner GL, O'Brien SM, Brewster L, Green MR, Schilsky RL. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. J Clin Oncol. 1995 Sep; 13(9):2230-7. PMID: 7545219.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    296. Ratain MJ, Rosner G, Allen SL, Costanza M, Van Echo DA, Henderson IC, Schilsky RL. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol. 1995 Mar; 13(3):741-7. PMID: 7884434.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    297. Miller AA, Hargis JB, Lilenbaum RC, Fields SZ, Rosner GL, Schilsky RL. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. J Clin Oncol. 1994 Dec; 12(12):2743-50. PMID: 7527456.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    298. Janisch L, Mick R, Schilsky RL, Vogelzang NJ, O'Brien S, Kut M, Ratain MJ. Prognostic factors for survival in patients treated in phase I clinical trials. Cancer. 1994 Oct 01; 74(7):1965-73. PMID: 8082103.
      Citations: 15     Fields:    Translation:Humans
    299. Kobayashi K, Vogelzang NJ, O'Brien SM, Schilsky RL, Vokes EE, Ratain MJ. A phase I study of intermittent infusion cladribine in patients with solid tumors. Cancer. 1994 Jul 01; 74(1):168-73. PMID: 7911736.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    300. Fleming GF, Ratain MJ, O'Brien SM, Schilsky RL, Hoffman PC, Richards JM, Vogelzang NJ, Kasunic DA, Earhart RH. Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. J Natl Cancer Inst. 1994 Mar 02; 86(5):368-72. PMID: 8308929.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    301. Vogelzang NJ, Mick R, Janisch L, Berezin F, Schilsky RL, Ratain MJ. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). Cancer Res. 1994 Jan 01; 54(1):114-9. PMID: 8261430.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    302. Mitchell RB, Dolan ME, Janisch L, Vogelzang NJ, Ratain MJ, Schilsky RL. Sequential therapy with dacarbazine and carmustine: a phase I study. Cancer Chemother Pharmacol. 1994; 34(6):509-14. PMID: 7923562.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    303. Mullane MR, Schilsky RL, Carroll RB, Wade JL, Kilton LJ, Blough RR, Bauman A, French SL, Benson AB. Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial. Invest New Drugs. 1994; 12(3):267-70. PMID: 7896548.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    304. Kilton LJ, Ashenhurst JB, Wade JL, Schilsky RL, Shiomoto G, Blough RR, French SL, Benson AB. Phase II study of fludarabine phosphate for gastric adenocarcinoma. An Illinois Cancer Center trial. Invest New Drugs. 1994; 12(2):163-6. PMID: 7532162.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    305. Devine S, Ratain M, Janisch L, Richards J, Williams S, Schilsky R, Vogelzang N, Skosey C. Phase-I trial of Thiotepa, granulocyte-macrophage colony-stimulating factor and prednisone or pentoxifylline in patients with refractory solid tumors. Oncol Rep. 1994 Jan; 1(1):213-6. PMID: 21607339.
      Citations:    Fields:    
    306. Ratain MJ, Mick R, Schilsky RL, Siegler M. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst. 1993 Oct 20; 85(20):1637-43. PMID: 8411243.
      Citations: 39     Fields:    Translation:Humans
    307. Samuels BL, Mick R, Vogelzang NJ, Williams SF, Schilsky RL, Safa AR, O'Brien SM, Ratain MJ. Modulation of vinblastine resistance with cyclosporine: a phase I study. Clin Pharmacol Ther. 1993 Oct; 54(4):421-9. PMID: 8222485.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    308. Lichtman SM, Ratain MJ, Van Echo DA, Rosner G, Egorin MJ, Budman DR, Vogelzang NJ, Norton L, Schilsky RL. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. J Natl Cancer Inst. 1993 Aug 18; 85(16):1319-26. PMID: 8340944.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    309. Vokes EE, Dolan ME, Krishnasamy S, Mick R, Ratain MJ, Berezin F, Brachman D, Whitman G, Schilsky RL, Charette J, et al. 5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis. Ann Oncol. 1993 Aug; 4(7):591-5. PMID: 8395874.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    310. Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Vogelzang NJ, Lane LB. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res. 1993 May 15; 53(10 Suppl):2304-8. PMID: 8485716.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    311. Kobayashi K, Schilsky RL. Update on biochemical modulation of chemotherapeutic agents. Oncology (Williston Park). 1993 May; 7(5):99-106, 109; discussion 110-4, 117. PMID: 8512789.
      Citations:    Fields:    Translation:Humans
    312. Schilsky RL, Janisch L, Berezin F, Mick R, Vogelzang NJ, Ratain MJ. Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer. Cancer Res. 1993 Mar 15; 53(6):1293-6. PMID: 7680282.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    313. Schilsky RL, Ratain MJ, Janisch L, Vogelzang NJ, Lucas VS, Ravitch J, Hohneker JA, Clendeninn NJ, Tuttle RL. Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion. Cancer Chemother Pharmacol. 1993; 31(4):283-8. PMID: 8422691.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    314. Vokes EE, O'Brien SM, Vogelzang NJ, Schilsky RL, Ratain MJ. Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study. Cancer Chemother Pharmacol. 1993; 32(5):347-52. PMID: 8339384.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    315. Fleming GF, Schilsky RL. Antifolates: the next generation. Semin Oncol. 1992 Dec; 19(6):707-19. PMID: 1462168.
      Citations: 9     Fields:    Translation:HumansAnimals
    316. Myers SE, Schilsky RL. Prospects for fertility after cancer chemotherapy. Semin Oncol. 1992 Oct; 19(5):597-604. PMID: 1411656.
      Citations: 3     Fields:    Translation:Humans
    317. Schilsky RL. Biochemical pharmacology of chemotherapeutic drugs used as radiation enhancers. Semin Oncol. 1992 Aug; 19(4 Suppl 11):2-7. PMID: 1509277.
      Citations: 5     Fields:    Translation:HumansAnimals
    318. Schilsky RL, Ratain MJ, Vokes EE, Vogelzang NJ, Anderson J, Peterson BA. Laboratory and clinical studies of biochemical modulation by hydroxyurea. Semin Oncol. 1992 Jun; 19(3 Suppl 9):84-9. PMID: 1641659.
      Citations: 4     Fields:    Translation:HumansAnimals
    319. Vokes EE, Haraf DJ, Panje WR, Schilsky RL, Weichselbaum RR. Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. Semin Oncol. 1992 Jun; 19(3 Suppl 9):53-8. PMID: 1641658.
      Citations: 6     Fields:    Translation:Humans
    320. Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Williams SF, Smiddy J. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther. 1991 Nov; 50(5 Pt 1):573-9. PMID: 1934870.
      Citations: 18     Fields:    Translation:HumansCells
    321. Oster MW, Schilsky RL, Faraggi D, Korzun AH, Perry M, Moore A, Kalra J, Wood WC, Henderson IC. Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the Cancer and Leukemia Group B. Cancer. 1991 Oct 15; 68(8):1696-8. PMID: 1913511.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    322. Schilsky RL, Faraggi D, Korzun A, Vogelzang N, Ellerton J, Wood W, Henderson IC. Phase II study of echinomycin in patients with advanced breast cancer: a report of Cancer and Leukemia Group B protocol 8641. Invest New Drugs. 1991 Aug; 9(3):269-72. PMID: 1783527.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    323. Ratain MJ, Mick R, Schilsky RL, Vogelzang NJ, Berezin F. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol. 1991 Aug; 9(8):1480-6. PMID: 2072147.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    324. Vokes EE, Raschko JW, Vogelzang NJ, Warfield EE, Ratain MJ, Doroshow JH, Schilsky RL. Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study. Cancer Chemother Pharmacol. 1991; 28(1):69-73. PMID: 1828191.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    325. Vokes EE, Ratain MJ, Janisch L, Hoffman PC, Golomb HM, Schilsky RL. A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients. Eur J Cancer. 1991; 27(2):217-8. PMID: 1827293.
      Citations:    Fields:    Translation:Humans
    326. Gradishar W, Vokes E, Schilsky R, Weichselbaum R, Panje W. Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience. Med Pediatr Oncol. 1991; 19(1):8-15. PMID: 1990260.
      Citations: 8     Fields:    Translation:Humans
    327. Schilsky RL, Choi KE, Grayhack J, Grimmer D, Guarnieri C, Fullem L. Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J Clin Oncol. 1990 Dec; 8(12):2054-61. PMID: 2230897.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    328. Ratain MJ, Schilsky RL, Conley BA, Egorin MJ. Pharmacodynamics in cancer therapy. J Clin Oncol. 1990 Oct; 8(10):1739-53. PMID: 2213109.
      Citations: 29     Fields:    Translation:Humans
    329. Schilsky RL, Ratain MJ. Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. J Natl Cancer Inst. 1990 Sep 05; 82(17):1411-5. PMID: 2388292.
      Citations: 15     Fields:    Translation:Humans
    330. Ringenberg QS, Propert KJ, Muss HB, Weiss RB, Schilsky RL, Modeas C, Perry MC, Norton L, Green M. Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report. Invest New Drugs. 1990 May; 8(2):221-6. PMID: 2166722.
      Citations:    Fields:    Translation:Humans
    331. Vokes EE, Schilsky RL, Weichselbaum RR, Kozloff MF, Panje WR. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1990 Feb; 8(2):241-7. PMID: 1688926.
      Citations: 12     Fields:    Translation:Humans
    332. Lee PP, Schilsky RL. Inhibition of thymidylate synthase by the diastereoisomers of leucovorin. Cancer Chemother Pharmacol. 1990; 26(4):273-7. PMID: 2114950.
      Citations: 6     Fields:    Translation:Cells
    333. Zacharski LR, Moritz TE, Haakenson CM, O'Donnell JF, Ballard HS, Johnson GJ, Ringenberg QS, Schilsky RL, Spaulding MB, Tornyos K, et al. Chronic calcium antagonist use in carcinoma of the lung and colon: a retrospective cohort observational study. Cancer Invest. 1990; 8(5):451-8. PMID: 2176124.
      Citations: 8     Fields:    Translation:Humans
    334. Green MR, Kramar A, Schilsky R, Stoopler M, Zimmer B, Richards F, Skarin A, Anderson JR. Platinum-based combination chemotherapy in advanced non-small cell lung cancer: a randomized phase II trial of the Cancer and Leukemia Group B. Med Pediatr Oncol. 1990; 18(3):197-202. PMID: 2158614.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    335. Gradishar WJ, Schilsky RL. Ovarian function following radiation and chemotherapy for cancer. Semin Oncol. 1989 Oct; 16(5):425-36. PMID: 2678491.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    336. Schilsky RL. Infertility in patients with testicular cancer: testis, tumor, or treatment? J Natl Cancer Inst. 1989 Aug 16; 81(16):1204-5. PMID: 2754737.
      Citations: 1     Fields:    Translation:Humans
    337. Hohl RJ, Schilsky RL. Nonmalignant complications of therapy for Hodgkin's disease. Hematol Oncol Clin North Am. 1989 Jun; 3(2):331-43. PMID: 2663831.
      Citations: 2     Fields:    Translation:Humans
    338. Vokes EE, Panje WR, Schilsky RL, Mick R, Awan AM, Moran WJ, Goldman MD, Tybor AG, Weichselbaum RR. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol. 1989 Jun; 7(6):761-8. PMID: 2715806.
      Citations: 12     Fields:    Translation:Humans
    339. Schilsky RL, Choi KE, Vokes EE, Guaspari A, Guarnieri C, Whaling S, Liebner MA. Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing. Cancer. 1989 Mar 15; 63(6 Suppl):1018-21. PMID: 2783878.
      Citations: 6     Fields:    Translation:Humans
    340. Vokes EE, Schilsky RL, Weichselbaum RR, Guaspari A, Guarnieri CM, Whaling SM, Panje WR. Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer. Cancer. 1989 Mar 15; 63(6 Suppl):1048-53. PMID: 2783881.
      Citations: 7     Fields:    Translation:Humans
    341. Schilsky RL. Male fertility following cancer chemotherapy. J Clin Oncol. 1989 Mar; 7(3):295-7. PMID: 2645384.
      Citations:    Fields:    Translation:HumansAnimalsCells
    342. Ratain MJ, Schilsky RL, Choi KE, Guarnieri C, Grimmer D, Vogelzang NJ, Senekjian E, Liebner MA. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther. 1989 Mar; 45(3):226-33. PMID: 2920497.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    343. Vokes EE, Schilsky RL, Choi KE, Magid DM, Guarnieri CM, Whaling SM, Ratain MJ, Weichselbaum RR, Panje WR. A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. Cancer. 1989 Jan 01; 63(1):30-6. PMID: 2910422.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    344. Magid DM, Vokes EE, Schilsky RL, Guarnieri CM, Whaling SM, Weichselbaum RR, Panje WR. A randomized study of inpatient versus outpatient continuous intravenous infusion chemotherapy: psychosocial aspects. Sel Cancer Ther. 1989; 5(3):137-45. PMID: 2682877.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    345. Ratain MJ, Schilsky RL, Wojack BR, Simon T, Senekjian EK, Vogelzang NJ. Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial. J Natl Cancer Inst. 1988 Nov 02; 80(17):1412-6. PMID: 3270508.
      Citations: 2     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    346. Ackland SP, Schilsky RL, Beckett MA, Weichselbaum RR. Synergistic cytotoxicity and DNA strand break formation by bromodeoxyuridine and bleomycin in human tumor cells. Cancer Res. 1988 Aug 01; 48(15):4244-9. PMID: 2455593.
      Citations: 3     Fields:    Translation:HumansCells
    347. Ratain MJ, Staubus AE, Schilsky RL, Malspeis L. Limited sampling models for amonafide (NSC 308847) pharmacokinetics. Cancer Res. 1988 Jul 15; 48(14):4127-30. PMID: 3383202.
      Citations: 13     Fields:    Translation:Humans
    348. Vokes EE, Panje WR, Weichselbaum RR, Schilsky RL, Moran WJ, Awan AM, Guarnieri CM. Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results. Otolaryngol Head Neck Surg. 1988 Apr; 98(4):295-8. PMID: 3132681.
      Citations:    Fields:    Translation:Humans
    349. Vokes EE, Choi KE, Schilsky RL, Moran WJ, Guarnieri CM, Weichselbaum RR, Panje WR. Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol. 1988 Apr; 6(4):618-26. PMID: 3258629.
      Citations: 10     Fields:    Translation:Humans
    350. Choi KE, Schilsky RL. Resolution of the stereoisomers of leucovorin and 5-methyltetrahydrofolate by chiral high-performance liquid chromatography. Anal Biochem. 1988 Feb 01; 168(2):398-404. PMID: 2834981.
      Citations: 6     Fields:    
    351. Gradishar WJ, Schilsky RL. Effects of cancer treatment on the reproductive system. Crit Rev Oncol Hematol. 1988; 8(2):153-71. PMID: 3046766.
      Citations: 4     Fields:    Translation:Humans
    352. Williams SF, Schilsky RL, Ultmann JE, Samuels BL. The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of malignant lymphomas. Cancer Invest. 1988; 6(4):427-37. PMID: 3052703.
      Citations:    Fields:    Translation:Humans
    353. Vokes EE, Moran WJ, Awan AM, Schilsky RL, Goldman M, Sutton HG, Weichselbaum RR, Panje WR. Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer. NCI Monogr. 1988; (6):353-6. PMID: 3352782.
      Citations:    Fields:    Translation:Humans
    354. Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. J Clin Oncol. 1987 Dec; 5(12):2017-31. PMID: 3316519.
      Citations: 44     Fields:    Translation:Humans
    355. Bennett CL, Sinkule JA, Schilsky RL, Senekjian E, Choi KE. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res. 1987 Apr 01; 47(7):1952-6. PMID: 3815383.
      Citations: 21     Fields:    Translation:Humans
    356. Schilsky RL, Williams SF, Ultmann JE, Watson S. Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin's lymphoma. J Clin Oncol. 1987 Mar; 5(3):419-25. PMID: 3819808.
      Citations: 8     Fields:    Translation:Humans
    357. Schilsky RL, Davidson HS, Magid D, Daiter S, Golomb HM. Gonadal and sexual function in male patients with hairy cell leukemia: lack of adverse effects of recombinant alpha 2-interferon treatment. Cancer Treat Rep. 1987 Feb; 71(2):179-81. PMID: 3100036.
      Citations: 2     Fields:    Translation:Humans
    358. Schilsky RL. Clinical implications of tumor heterogeneity. Haematol Blood Transfus. 1987; 31:278-82. PMID: 3327773.
      Citations: 3     Fields:    Translation:Humans
    359. Ratain MJ, Schilsky RL. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Cancer Res. 1986 Sep; 46(9):4874. PMID: 2942243.
      Citations:    Fields:    Translation:Humans
    360. Schilsky RL, O'Laughlin K, Ratain MJ. Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer. Cancer Res. 1986 Aug; 46(8):4184-8. PMID: 3731086.
      Citations: 2     Fields:    Translation:Humans
    361. Schilsky RL. Tumor cell heterogeneity: implications for clinical practice. Semin Oncol. 1985 Sep; 12(3):203-6. PMID: 4048963.
      Citations: 2     Fields:    Translation:HumansCells
    362. Schilsky RL, Green MR, Anderson J. Cytarabine-cis-platin interactions in patients with advanced cancer. Semin Oncol. 1985 Jun; 12(2 Suppl 3):171-6. PMID: 4040265.
      Citations:    Fields:    Translation:Humans
    363. Schilsky RL, Ordway FS. Simultaneous determination of cytosine arabinoside, its nucleotides and metabolites by ion-pair high-performance liquid chromatography. J Chromatogr. 1985 Jan 11; 337(1):63-71. PMID: 3980658.
      Citations: 1     Fields:    Translation:AnimalsCells
    364. Schilsky RL, Ordway FS. Insulin effects on methotrexate polyglutamate synthesis and enzyme binding in cultured human breast cancer cells. Cancer Chemother Pharmacol. 1985; 15(3):272-7. PMID: 2414022.
      Citations: 1     Fields:    Translation:HumansCells
    365. Schilsky RL, Muscato JJ, Muscato MS, Perry MC. Phase I clinical evaluation of cytarabine and cisplatin in patients with advanced cancer. Cancer Treat Rep. 1984 Sep; 68(9):1097-102. PMID: 6541094.
      Citations: 1     Fields:    Translation:Humans
    366. Schilsky RL, Jolivet J, Bailey BD, Chabner BA. Synthesis, binding and intracellular retention of methotrexate polyglutamates by cultured human breast cancer cells. Adv Exp Med Biol. 1983; 163:247-57. PMID: 6193688.
      Citations: 1     Fields:    Translation:HumansCells
    367. Jolivet J, Schilsky RL, Bailey BD, Chabner BA. The synthesis and retention of methotrexate polyglutamates in cultured human breast cancer cells. Ann N Y Acad Sci. 1982 Dec 10; 397:184-92. PMID: 6186175.
      Citations: 3     Fields:    Translation:HumansCells
    368. Schilsky RL, Barlock A, Ozols RF. Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep. 1982 Sep; 66(9):1767-9. PMID: 6889461.
      Citations: 23     Fields:    Translation:Humans
    369. Jolivet J, Schilsky RL, Bailey BD, Drake JC, Chabner BA. Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. J Clin Invest. 1982 Aug; 70(2):351-60. PMID: 6178756; PMCID: PMC371243.
      Citations: 33     Fields:    Translation:HumansCells
    370. Schilsky RL, Kelley JA, Ihde DC, Howser DM, Cordes RS, Young RC. Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans. Cancer Res. 1982 Apr; 42(4):1582-6. PMID: 7060028.
      Citations: 10     Fields:    Translation:Humans
    371. Schilsky RL. Renal and metabolic toxicities of cancer chemotherapy. Semin Oncol. 1982 Mar; 9(1):75-83. PMID: 7200263.
      Citations: 6     Fields:    Translation:Humans
    372. Schilsky RL, Sherins RJ, Hubbard SM, Wesley MN, Young RC, DeVita VT. Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. Am J Med. 1981 Oct; 71(4):552-6. PMID: 7282743.
      Citations: 18     Fields:    Translation:Humans
    373. Schilsky RL, Bailey BD, Chabner BA. Characteristics of membrane transport of methotrexate by cultured human breast cancer cells. Biochem Pharmacol. 1981 Jun 15; 30(12):1537-42. PMID: 7023485.
      Citations: 5     Fields:    Translation:HumansCells
    374. Jolivet J, Schilsky RL. High-pressure liquid chromatography analysis of methotrexate polyglutamates in cultured human breast cancer cells. Biochem Pharmacol. 1981 Jun 01; 30(11):1387-90. PMID: 6168268.
      Citations: 10     Fields:    Translation:HumansCells
    375. Chabner BA, Donehower RC, Schilsky RL. Clinical pharmacology of methotrexate. Cancer Treat Rep. 1981; 65 Suppl 1:51-4. PMID: 6799198.
      Citations: 6     Fields:    Translation:HumansAnimals
    376. Schilsky RL, Lewis BJ, Sherins RJ, Young RC. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med. 1980 Jul; 93(1):109-14. PMID: 6994532.
      Citations: 30     Fields:    Translation:Humans
    377. Schilsky RL, Bailey BD, Chabner BA. Methotrexate polyglutamate synthesis by cultured human breast cancer cells. Proc Natl Acad Sci U S A. 1980 May; 77(5):2919-22. PMID: 6156458; PMCID: PMC349517.
      Citations: 14     Fields:    Translation:HumansCells
    378. Longo DL, Schilsky RL, Blei L, Cano R, Johnston GS, Young RC. Gallium-67 scanning: limited usefulness in staging patients with non-Hodgkin's lymphoma. Am J Med. 1980 May; 68(5):695-700. PMID: 6769331.
      Citations: 3     Fields:    Translation:Humans
    379. Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC, Muggia FM. Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep. 1979 Sep-Oct; 63(9-10):1527-31. PMID: 387223.
      Citations: 111     Fields:    Translation:Humans
    380. Anderson T, Javadpour N, Schilsky R, Barlock A, Young RC. Chemotherapy for testicular cancer: current status of the National Cancer Institute Combined Modality Trial. Cancer Treat Rep. 1979 Sep-Oct; 63(9-10):1687-92. PMID: 91439.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    381. Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med. 1979 Jun; 90(6):929-31. PMID: 375794.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    Schilsky's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (775)
    Explore
    _
    Co-Authors (27)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _